<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000377.pub2" GROUP_ID="BEHAV" ID="772299082010145044" MERGED_FROM="" MODIFIED="2008-11-12 11:08:28 +0100" MODIFIED_BY="Julie Millener" REVIEW_NO="1002" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.6">
<COVER_SHEET MODIFIED="2008-11-12 11:08:28 +0100" MODIFIED_BY="Julie Millener">
<TITLE>Antipsychotic medication for challenging behaviour in people with learning disability</TITLE>
<CONTACT MODIFIED="2008-11-12 11:08:28 +0100" MODIFIED_BY="Julie Millener"><PERSON ID="7396" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lorna</FIRST_NAME><LAST_NAME>Duggan</LAST_NAME><POSITION>Director of Clinical Services</POSITION><EMAIL_1>lornaduggan@yahoo.co.uk</EMAIL_1><EMAIL_2>Lorna.Duggan@careprinciples.com</EMAIL_2><MOBILE_PHONE>07843527047</MOBILE_PHONE><ADDRESS><ORGANISATION>Care Principles Ltd</ORGANISATION><ADDRESS_1>Oaks Lodge, Fordham Road</ADDRESS_1><CITY>Newmarket</CITY><ZIP>CB8 7XN</ZIP><REGION>Suffolk</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1604 616563</PHONE_1><FAX_1>+44 1604 616620</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-12 11:08:28 +0100" MODIFIED_BY="Julie Millener"><PERSON ID="7238" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jane</FIRST_NAME><LAST_NAME>Brylewski</LAST_NAME><EMAIL_1>jane.b@btinternet.com</EMAIL_1><ADDRESS><ORGANISATION/><CITY>Oxford</CITY><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 228101</PHONE_1><FAX_1>+44 1865 228182</FAX_1></ADDRESS></PERSON><PERSON ID="7396" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lorna</FIRST_NAME><LAST_NAME>Duggan</LAST_NAME><POSITION>Director of Clinical Services</POSITION><EMAIL_1>lornaduggan@yahoo.co.uk</EMAIL_1><EMAIL_2>Lorna.Duggan@careprinciples.com</EMAIL_2><MOBILE_PHONE>07843527047</MOBILE_PHONE><ADDRESS><ORGANISATION>Care Principles Ltd</ORGANISATION><ADDRESS_1>Oaks Lodge, Fordham Road</ADDRESS_1><CITY>Newmarket</CITY><ZIP>CB8 7XN</ZIP><REGION>Suffolk</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1604 616563</PHONE_1><FAX_1>+44 1604 616620</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-11 14:47:50 +0000" MODIFIED_BY="Cathy Bennett">
<UP_TO_DATE>
<DATE DAY="1" MONTH="12" YEAR="2003"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="12" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-11 14:46:50 +0000" MODIFIED_BY="Cathy Bennett">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-11 14:43:27 +0000" MODIFIED_BY="Cathy Bennett">
<DATE DAY="11" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-11 14:46:50 +0000" MODIFIED_BY="Cathy Bennett">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="20" MONTH="4" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-11 14:46:41 +0000" MODIFIED_BY="Cathy Bennett">
<DATE DAY="1" MONTH="12" YEAR="2003"/>
<DESCRIPTION>
<P>Search strategy updated in December 2003. Text modified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-11 14:46:44 +0000" MODIFIED_BY="Cathy Bennett">
<DATE DAY="21" MONTH="2" YEAR="2001"/>
<DESCRIPTION>
<P>New studies sought but but not yet included or excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-11 14:46:47 +0000" MODIFIED_BY="Cathy Bennett">
<DATE DAY="2" MONTH="1" YEAR="2001"/>
<DESCRIPTION>
<P>Minor update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-11 14:46:50 +0000" MODIFIED_BY="Cathy Bennett">
<DATE DAY="25" MONTH="10" YEAR="1999"/>
<DESCRIPTION>
<P>Reformatted</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Oxfordshire Learning Disability NHS Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>West Berkshire Priority Care NHS Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>St Andrew's Hospital, Northampton</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-11 20:26:12 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-11 14:49:56 +0000" MODIFIED_BY="Cathy Bennett">
<TITLE MODIFIED="2008-11-11 14:48:56 +0000" MODIFIED_BY="Cathy Bennett">Antipsychotic medication for challenging behaviour in people with learning disability</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-11 14:49:56 +0000" MODIFIED_BY="Cathy Bennett">
<P>The term 'challenging behaviour', in the absence of psychiatric disorder, encompasses a wide range of behaviours that may be harmful to people or property, may be difficult to manage and may limit access to community facilities. Antipsychotic medications have been used to modify such behaviours in people with learning disability, but there is no randomised controlled trial-based information that suggests antipsychotic medication is either helpful or harmful for adults with learning disability and challenging behaviour.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>The term 'challenging behaviour', in the absence of psychiatric disorder, encompasses a wide range of behaviours that may be harmful to people or property, may be difficult to manage and may limit access to community facilities. Antipsychotic medications have been used to modify such behaviours in people with learning disability, but there is little evidence to suggest that the benefits outweigh the risks.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effectiveness of antipsychotic medication for people with learning disability and challenging behaviour without additional mental illness.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Biological Abstracts, the Cochrane Library, EMBASE, MEDLINE, PsycINFO and BIOSIS were searched. Further references were sought from published trials and pharmaceutical companies. Trials were reliably identified and data extracted.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised controlled trials of antipsychotic medication versus placebo.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Reviewers independently evaluated and analysed data on an intention to treat basis. Data were evaluated at 4, 8 and 12 weeks as longer follow-up data were not available. Reviewers assumed that those subjects lost to follow-up had a bad outcome.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Only nine randomised controlled trials could be included in the analyses. These provided no evidence of whether antipsychotic medication helps or harms adults with learning disability and challenging behaviour.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There are limited data on this important issue and more research is urgently needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-11 20:26:12 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-11-11 14:50:55 +0000" MODIFIED_BY="Cathy Bennett">
<CONDITION MODIFIED="2008-11-11 14:50:49 +0000" MODIFIED_BY="Cathy Bennett">
<P>For the purpose of this review we use the term 'learning disability' to describe those people with a significant impairment of intelligence and social functioning with onset in the first eighteen years of life. This corresponds to 'mental retardation' as described in the major taxonomies DSM IV (APA 1994) and ICD 10 (<LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>).</P>
<P>The currently favoured definition of 'challenging behaviour' is 'culturally abnormal behaviour(s) of such intensity, frequency or duration that the physical safety of the person or others is likely to be placed in serious jeopardy, or behaviour which is likely to seriously limit use of, or result in the person being denied access to, ordinary community facilities' (<LINK REF="REF-Emerson-1995" TYPE="REFERENCE">Emerson 1995</LINK>). 'Challenging behaviour' and 'behaviour disorder' now replace older terms including abnormal, aberrant, disordered, disturbed, maladaptive and problem behaviours. It describes a range of behaviours including aggression, destructiveness, self-injury and stereotyped repetitive behaviours that may be harmful for the individual, challenging for carers and/or objectionable to the general public.</P>
<P>The social context of challenging behaviour is paramount; the same behaviour may be seen as challenging in one situation but appropriate in another. For example shouting is permissible at a football match but not in church. The social context is relevant to the construction of intervention strategies and allows them to be socially valid. Outcome measures in research on challenging behaviour should not confine themselves to the frequency, duration and intensity of the target behaviours but include equally meaningful outcomes that take the social context into account. These include acquired replacement skills (for example, self-control), strategies to support behaviour change and development of alternative communication responses. In addition, the nature of the procedures used to manage the person's challenging behaviour, for example medication, restraint, crisis management, restrictive residential and vocational placement, are all important, as are the quality of life and perceived significance of the person's challenging behaviour by family, staff and public (<LINK REF="REF-Emerson-1995" TYPE="REFERENCE">Emerson 1995</LINK>).</P>
<P>With these considerations in mind it is not surprising that prevalence studies of challenging behaviour in people with learning disability have yielded a wide range of results. The diagnosis of challenging behaviour, implies that formal psychiatric disorder such as schizophrenia or affective disorder has been excluded. The diagnosis of a specific psychiatric disorder becomes more difficult as the severity of the learning disability increases because symptoms and signs of illness become ever more difficult to elucidate and interpret. For example, behavioural disturbances that might be symptomatic of mental illness in someone of normal intelligence could have other explanations in a person with learning disability. This may also be a factor in the increased prevalence of challenging behaviour in more disabled groups. In general, rates are higher in more disabled people, that is those with poor communication skills and those living in institutional rather than community settings. In 1993 a community study reported rates of 17.6% for aggression (<LINK REF="REF-Harris-1993" TYPE="REFERENCE">Harris 1993</LINK>) whilst Deb and Hunter (<LINK REF="REF-Deb-1991" TYPE="REFERENCE">Deb 1991</LINK>) found rates of 55.3% amongst 300 people from community and hospital settings. Early research gave higher rates in those with epilepsy although more recently this has been challenged (<LINK REF="REF-Eyman-1969" TYPE="REFERENCE">Eyman 1969</LINK>, <LINK REF="REF-Capes-1970" TYPE="REFERENCE">Capes 1970</LINK>, <LINK REF="REF-Deb-1991" TYPE="REFERENCE">Deb 1991</LINK>).</P>
<P>Historically, challenging behaviour has been the domain of the clinical psychologist using behavioural approaches. Despite research highlighting how few people with difficult behaviours receive behavioural interventions (<LINK REF="REF-Oliver-1987" TYPE="REFERENCE">Oliver 1987</LINK>), functional analysis has important implications for understanding challenging behaviour. When a functional view is taken, one can see that different behaviours might have similar functions as far as securing desired goals. For example both aggression and pica (the eating of non-food substances) may at different times in the same person serve to avoid certain stresses. In addition, similar behaviours might be used by different people to secure different goals. For example one person might use aggression to obtain adult attention whereas another person could use it to escape unwanted attention. Most trials of antipsychotic medication for challenging behaviour include people who vary on the functional nature of the behaviour (<LINK REF="REF-Schaal-1994" TYPE="REFERENCE">Schaal 1994</LINK>) so, within an overview such as this, some more subtle effects may not be apparent because of this heterogeneity of function of the challenging behaviours.</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-11-11 14:50:43 +0000" MODIFIED_BY="Cathy Bennett">
<P>Antipsychotics were introduced into psychiatric practice in the 1950's, initially with chlorpromazine followed by a host of other medications with a similar action in the brain. Their usefulness in the treatment of schizophrenia is accepted. Soon after its introduction in the treatment of schizophrenia the first reports of chlorpromazine's use in the treatment of people with learning disability and challenging behaviour were published (<LINK REF="REF-Bair-1955" TYPE="REFERENCE">Bair 1955</LINK>). Recent studies into the prescribing of antipsychotic medication revealed that almost half of an institutional population were taking such medication (<LINK REF="REF-Linaker-1990" TYPE="REFERENCE">Linaker 1990</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2008-11-11 14:50:30 +0000" MODIFIED_BY="Cathy Bennett">
<P>Conflicting results have been published as to whether people with learning disability, when exposed to antipsychotic medication, are at increased risk of developing unpleasant, and potentially disabling, short-term and long-term side-effects. It has been argued that as a consequence of their underlying neurological damage, people with learning disability may be at greater risk of developing movement disorders (<LINK REF="REF-Youseff-1988" TYPE="REFERENCE">Youseff 1988</LINK>, <LINK REF="REF-Rogers-1991" TYPE="REFERENCE">Rogers 1991</LINK>, <LINK REF="REF-Sachdev-1992" TYPE="REFERENCE">Sachdev 1992</LINK>, <LINK REF="REF-Gingell-1994" TYPE="REFERENCE">Gingell 1994</LINK>). Aman (<LINK REF="REF-Aman-1984" TYPE="REFERENCE">Aman 1984</LINK>) has also raised concerns regarding the detrimental effects of antipsychotic medication on learning and cognitive abilities in people with learning disability. The widespread use of antipsychotic medication for those with learning disabilities has been questioned and drug reduction programmes are now mandatory in some states in the USA (<LINK REF="REF-Rinck-1989" TYPE="REFERENCE">Rinck 1989</LINK>).</P>
<P>Reviews have been published about the efficacy of antipsychotic medication in people with both learning disability and challenging behaviour (<LINK REF="REF-Manchester-1993" TYPE="REFERENCE">Manchester 1993</LINK>). These have been traditional in style and have not contained a methods section in order to allow for replication.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>The primary objective of this review was to determine the clinical effectiveness and safety of antipsychotic medication for treating people with both challenging behaviour and learning disability.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-11 20:26:12 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-11 15:22:26 +0000" MODIFIED_BY="Cathy Bennett">
<CRIT_STUDIES>
<P>Unconfounded randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults (those over 18 years of age) with both learning disability (however diagnosed) and challenging behaviour (however diagnosed) without a superimposed mental illness. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-11-11 14:48:28 +0000" MODIFIED_BY="Cathy Bennett">
<P>Any antipsychotic medication, regardless of dosage, versus a placebo control, of longer than one month's duration.</P>
<P>The definition of antipsychotic medication used was that given in the British National Formulary (<LINK REF="REF-BNF-2001" TYPE="REFERENCE">BNF 2001</LINK>) section 4.2.1 and 4.2.2, in addition to that described in the individual trials:</P>
<P>Phenothiazine group - chlorpromazine, fluphenazine, methotrimeprazine, pericyazine, perphenazine, pipotiazine, prochlorperazine, promazine, thioridazine, trifluoperazine.</P>
<P>Butyrophenone group - benperidol and haloperidol.</P>
<P>Diphenylbutylpiperidine group - pimozide.</P>
<P>Thioxanthene group - flupentixol and zuclopenthixol.</P>
<P>Substituted benzamide group - sulpiride.</P>
<P>Tricyclic dibenzoxazepine group - loxapine and oxypertine.</P>
<P>Newer antipsychotic drugs (atypical antipsychotics) - amisulpiride, clozapine, olanzapine, quetiapine, risperidone, sertindole and zotiepine.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-11 15:22:26 +0000" MODIFIED_BY="Cathy Bennett">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-11-11 15:22:26 +0000" MODIFIED_BY="Cathy Bennett">
<P>1. Challenging behaviours<BR/>a. aggressive/violent behaviours (includes sexually aggressive acts) to others;<BR/>b. aggressive behaviours to self; and<BR/>c. non-aggressive challenging behaviours.<BR/>2. General social functioning such as self care.<BR/>3. Adverse effects such as sleepiness, movement disorders, number of falls and fits.<BR/>4. Acceptability of care as measured by the number of people dropping out from the study.</P>
<P>We recognised that different target behaviours would be recorded for different individuals. We used the study authors' definitions of 'challenging behaviour' for both 'aggressive' and 'non-aggressive' behaviours.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-11-11 15:18:48 +0000" MODIFIED_BY="Cathy Bennett">
<OL>
<LI>Satisfaction of client or primary carer;</LI>
<LI>Non-specific general improvement in behaviour;</LI>
<LI>Economic outcomes if available;</LI>
<LI>Physical morbidity and mortality;</LI>
<LI>Outcomes related to pace of learning.</LI>
</OL>
<P>It was hoped to group outcome data into immediate (less than 1 week), short (1 week-6 months), medium (7-12 months) and long (over 1 year) term. Where an outcome had not been prestated to be of primary or secondary interest but was found in studies, thought to be of importance, and no threat to the validity of the review, this was included and the post hoc nature of its inclusion noted.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-11 20:14:15 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-11-11 20:14:15 +0000" MODIFIED_BY="[Empty name]">
<P>A new search strategy was devised and run in December 2003 for this updated version of the review for the following databases:</P>
<P>CENTRAL (The Cochrane Library) (Up to 2003 (4)) using the search strategy in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>MEDLINE (1966 - Dec 2003) was searched using Ovid online using the search strategy in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>EMBASE (1980 - December 2003) was searched using Ovid online using the search strategy in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
<P>PsycINFO (1887 - December 2003) was searched using the search strategy in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
<P>BIOSIS (Biological Abstracts) (January 1980 to December 2003) was searched using the search strategy in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-11 15:00:51 +0000" MODIFIED_BY="Cathy Bennett">
<P>Citations of all selected trials were searched for additional studies and citations of selected studies were searched for in the ISI citation database in order to identify further material.</P>
<P>Companies producing antipsychotic medication were contacted and requests for additional studies both published and unpublished were made.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-11 20:26:12 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2008-11-11 15:02:24 +0000" MODIFIED_BY="Cathy Bennett">
<P>All reports of studies identified as above were inspected, independently, by each reviewer. Where disagreement occurred regarding the possible relevance of the study this was resolved by discussion, or where there was still doubt, the full article was acquired for further inspection. Once the full articles were obtained each reviewer, independently, decided whether they met the review criteria. Reviewers were not blinded to the names of the authors, institutions or journal of publication. Again, where disagreement occurred this was resolved by discussion and when this was not possible further information was sought. These trials were added to the list of those awaiting assessment pending acquisition of further information.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-11 15:02:27 +0000" MODIFIED_BY="Cathy Bennett">
<P>Data were independently extracted by each reviewer and disagreements resolved by discussion. Where no data could be extracted, or further information was needed, the trial was added to the list of those awaiting assessment and the first author contacted for clarification. Where data could be extracted, comments on the methods, participants, interventions and outcomes are presented in the 'Included Studies' table.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-11-11 15:02:31 +0000" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">Assessment of methodological quality</HEADING>
<P>Reviewers allocated trials to three quality categories, (A - low risk of bias, B - moderate risk of bias and C - high risk of bias) as described in the Cochrane Collaboration Handbook (<LINK REF="REF-Clarke-2001" TYPE="REFERENCE">Clarke 2001</LINK>). Disagreement was resolved by discussion and where this was not possible the study was assigned to those awaiting assessment and the first author contacted for clarification. Only studies rated A or B were included.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-11-11 20:26:09 +0000" MODIFIED_BY="[Empty name]">
<P>Binary outcomes: if summation of data was appropriate and possible, the Peto Odds Ratio statistic was calculated.</P>
<P>Continuous outcomes: where there was more than 50% dropout from a study, data from continuous measures were felt to be too prone to bias and were therefore not reported. Only data from validated scales were reported and data were tested for the degree of skew. The reviewers decided not to add data across scales, but if possible, display similar scales on the same graphical display.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-11-11 15:02:56 +0000" MODIFIED_BY="Cathy Bennett">
<P>Tests for heterogeneity: the reviewers would have checked whether the differences among results of trials were greater than could be expected by chance alone. This would have been done by looking at the graphical display of the results and also by using tests of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-11-11 20:26:12 +0000" MODIFIED_BY="[Empty name]">
<P>In all cases the data were entered into RevMan in such a way that the area to the left of the 'line of no effect' indicates a 'favourable' outcome for antipsychotic management. Data were inspected within a funnel plot to identify a relationship between study size and size of treatment effect, such as might be caused by publication bias.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-11 15:23:42 +0000" MODIFIED_BY="Cathy Bennett">
<STUDY_DESCRIPTION MODIFIED="2008-11-11 15:23:42 +0000" MODIFIED_BY="Cathy Bennett">
<SEARCH_RESULTS MODIFIED="2008-11-11 15:04:19 +0000" MODIFIED_BY="Cathy Bennett">
<P>Over 600 (1000) citations were found using the search strategy, 71(150) qualified for further inspection. Of these, 22(28) proved to be randomised controlled trials, nine of which were relevant to this review. No unpublished trials were provided in response to requests made to pharmaceutical companies and no additional studies were identified from citations. A PhD dissertation was sent to the authors (<LINK REF="STD-Wright-1993" TYPE="STUDY">Wright 1993</LINK>) and was excluded. Although only four reports contained extractable information, all data, except for the outcome of 'Leaving the study early', is from two trials (<LINK REF="STD-de-Koning-1994" TYPE="STUDY">de Koning 1994</LINK>, <LINK REF="STD-McDougle-1998" TYPE="STUDY">McDougle 1998</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-11-11 15:23:39 +0000" MODIFIED_BY="Cathy Bennett">
<P>Please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. The nine included studies were described as "randomised" and "double-blind". The participant groups were adults with learning disabilities of moderate to profound degree except for (<LINK REF="STD-McDougle-1998" TYPE="STUDY">McDougle 1998</LINK>) which focused on adults with autistic disorder of which a minority were of normal intelligence. Some of the data were presented as individual patient data. The numbers in the studies were small (ranging from 18 to 160) but did contain people of either sex displaying challenging behaviour without an underlying mental illness. Lack of presentation of usable data was a frequent problem.</P>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>The interventions were SCH-12679, eltoprazine, milenperone, thioridazine, pipothiazine palmitate, prothipendyl, penfluridol, pipamperone and risperidone compared to placebo. Only thioridazine, pipothiazine palmitate and risperidone are to be found in the British National Formulary (BNF 2001) and due to adverse effects thioridazine can only be prescribed as a second-line treatment for schizophrenia in the United Kingdom.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>The most consistently reported outcome was leaving the study early. In all nine studies the primary outcome of interest, aggression or problematic behaviour, was reported in such as way as to make it unusable for this review. Albert (<LINK REF="STD-Albert-1977" TYPE="STUDY">Albert 1977</LINK>) presented average scores on two scales without the variance around the mean (standard deviation / standard error). <LINK REF="STD-de-Koning-1994" TYPE="STUDY">de Koning 1994</LINK> did report skewed but presentable data (see 'Other data' tables) from two scales and (<LINK REF="STD-McDougle-1998" TYPE="STUDY">McDougle 1998</LINK>) reported aggression using a non-validated scale. The other studies reported data that did not allow extraction for adults.</P>
<OL>
<LI>the Overt Aggression Scale (<LINK REF="REF-Yudofsky-1986" TYPE="REFERENCE">Yudofsky 1986</LINK>) is an observer rated scale measuring aggressive behaviours in children and adults. There are four categories; verbal aggression, physical aggression against objects, physical aggression against self and physical aggression against others. High score indicates poor outcome.</LI>
<LI>Social Dysfunction and Aggression Scale - self-mutilation item (<LINK REF="REF-ERAG-1992" TYPE="REFERENCE">ERAG 1992</LINK>) is a psychiatrist rated scale measuring clinical or psychopathological aggression. High score indicates poor outcome.</LI>
<LI>Ritvo-Freeman Real-life Rating Scale - (<LINK REF="REF-Freeman-1986" TYPE="REFERENCE">Freeman 1986</LINK>) is an observational measure of a variety of symptoms of autism comprising of five subscales: (I) sensory motor behaviours (eg hand-flapping, rocking, pacing), (II) social relationship to people (e.g. appropriate responses to interaction attempts, initiating appropriate physical interactions), (III) affectual reactions (e.g. abrupt changes in affect, crying, temper outbursts), (IV) sensory responses (e.g. agitated by noises, rubbing surfaces, sniffing self or objects) and (V) language (e.g. communicative use of language, initiating appropriate verbal communication). High score indicates greater severity of autistic symptoms.</LI>
<LI>Clinical Global Impression Scale - CGI Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)</LI>
<LI>This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven-point scoring system is usually used with low scores showing decreased severity and/or overall improvement.</LI>
</OL>
<P>
<LINK REF="STD-van-Hemert-1975" TYPE="STUDY">van Hemert 1975</LINK> presented limited, unusable, data on a non-peer reviewed scale (see guidelines in CSG Module, Cochrane Library).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-11-11 15:23:42 +0000" MODIFIED_BY="Cathy Bennett">
<P>Thirty three studies were excluded, 25 of which were randomised or described as "double-blind". It was common for studies to be excluded because of heterogeneity of participants and data could not be extracted for the population of interest. The reviewers wished to evaluate the value of antipsychotic medication for adults with learning disability and challenging behaviour but without mental illness.</P>
<P>Two studies (<LINK REF="STD-Ahmed-2000" TYPE="STUDY">Ahmed 2000</LINK>, <LINK REF="STD-Izmeth-1988" TYPE="STUDY">Izmeth 1988</LINK>) were randomised drug withdrawal studies and were excluded as they are not the focus of this review. Another study, (<LINK REF="STD-Zarcone-2002" TYPE="STUDY">Zarcone 2002</LINK>) although described as a comparison between risperidone and placebo, was a comparison of high dose and low dose risperidone.</P>
<P>Some studies failed to present the numbers randomised to each group (<LINK REF="STD-Vanden-Borre-1993" TYPE="STUDY">Vanden Borre 1993</LINK>; <LINK REF="STD-Sime-1974" TYPE="STUDY">Sime 1974</LINK> ) and frequently full data relating to continuous outcomes were not presented. Crossover studies, a questionable methodology for these interventions, often fail to present data for the first arm of the trial. In the only crossover study that presented potentially usable first arm data a typographical error resulted in study exclusion (<LINK REF="STD-Lindholm-1967" TYPE="STUDY">Lindholm 1967</LINK>). One study (<LINK REF="STD-Wright-1993" TYPE="STUDY">Wright 1993</LINK>) presented no usable data although the study was a randomised controlled trial comparing haloperidol, thioridazine and placebo in 18 severely learning disabled adults. Please see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-11 15:06:51 +0000" MODIFIED_BY="Cathy Bennett">
<P>The overall quality of the nine included studies was not good. Although all stated that the allocation was randomised only one study (<LINK REF="STD-McDougle-1998" TYPE="STUDY">McDougle 1998</LINK>) further described the process. The outcomes were, however, rated by blinded workers although only half described the limited means by which this was achieved (<LINK REF="STD-Albert-1977" TYPE="STUDY">Albert 1977</LINK>; <LINK REF="STD-De-Cuyper-1985" TYPE="STUDY">De Cuyper 1985</LINK>; <LINK REF="STD-Elie-1980" TYPE="STUDY">Elie 1980</LINK>; <LINK REF="STD-Zwanikken-1973" TYPE="STUDY">Zwanikken 1973</LINK>; <LINK REF="STD-McDougle-1998" TYPE="STUDY">McDougle 1998</LINK>).</P>
<P>The studies ranged in duration from 28 days to six months. The first 4 authors of de Koning (<LINK REF="STD-de-Koning-1994" TYPE="STUDY">de Koning 1994</LINK>) were employed by the manufacturers of the experimental intervention.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-11 15:23:42 +0000" MODIFIED_BY="Cathy Bennett">
<P>Of the primary outcomes of interest, data were only available for challenging behaviour (aggressive/violent behaviours to others as evaluated using the Overt Aggression Scale) and aggressive behaviours to self (evaluated using the Social Dysfunction and Aggression Scale - self-mutilation data). There was some dichotomous information on adverse effects and the acceptability of care as measured by the number of people dropping out of the study. Of the secondary outcomes of interest data were only extractable regarding non-specific general improvement in behaviour, evaluated using a dichotomous clinical evaluation or CGI.</P>
<SUBSECTION>
<HEADING LEVEL="3">Challenging behaviour</HEADING>
<P>
<LINK REF="STD-de-Koning-1994" TYPE="STUDY">de Koning 1994</LINK> presented data on global impression of behaviour and there was too much uncertainty to comment on the difference between eltoprazine and placebo at 8 weeks (OR 0.7, 95%CI 0.34-1.42; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). This study also presented data for other 'proxy' measures of behaviour none of which showed statistically significant differences between experimental and control groups (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Skewed scale data from the same study (<LINK REF="STD-de-Koning-1994" TYPE="STUDY">de Koning 1994</LINK>) relating to aggressive/violent behaviours to others or self could not be presented graphically but scrutiny of the numbers in the 'Other data' tables (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>) shows no overt or clinically important differences between the groups. <LINK REF="STD-McDougle-1998" TYPE="STUDY">McDougle 1998</LINK> reported CGI data that favoured risperidone over placebo in this small study. Difference in autistic symptoms, rated on the Ritvo-Freeman Real-life Rating Scale, were not statistically significant (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>Again, only two studies (<LINK REF="STD-de-Koning-1994" TYPE="STUDY">de Koning 1994</LINK>, <LINK REF="STD-McDougle-1998" TYPE="STUDY">McDougle 1998</LINK>) reported extractable adverse effect data. No differences between eltoprazine and placebo emerged for agitation, dizziness, gastrointestinal upsets or sleep disturbances, whereas risperidone produced more somnolence than placebo. Weight gain and enuresis was apparent with risperidone and more complained of any adverse effect in the risperidone group. Please see <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Leaving the study early</HEADING>
<P>Data were reported in four studies. There were no discernible differences between groups in the proportion of people leaving the studies, for whatever reason (OR 1.32, 95% CI 0.39-4.49; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-11 15:12:55 +0000" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="2">Generalisability of studies</HEADING>
<P>Eight studies were similar in that all participants were inpatients, often institutionalised for years. The most recent study (<LINK REF="STD-McDougle-1998" TYPE="STUDY">McDougle 1998</LINK>) included mostly outpatients with pervasive developmental disorders, reflecting the move to community care. As most people with learning disability and challenging behaviour are not in hospital or institutions this must limit the generalisability of any findings. In addition, the interventions trialed except for risperidone, (SCH-12679, eltoprazine, milenperone, thioridazine, pipothiazine palmitate, prothipendyl, penfluridol and pipamperone) are not all universally available, again limiting generalisability of the results. Those with learning disability and challenging behaviour often are difficult to manage over years, if not decades. Any information from trials does not extend beyond six months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Results</HEADING>
<P>There is no randomised controlled trial-based information that suggests antipsychotic medication is either helpful or harmful for adults with learning disability and challenging behaviour. This review has highlighted the lack of good quality trials conducted in this field. It could be said that the reviewers used over-strict inclusion criteria, excluding data from studies where participants were, in the majority under 18 years of age or suffering from concurrent mental illness. In order to address this possible comment subsequent versions of the companion review to this (<LINK REF="REF-Duggan-2001" TYPE="REFERENCE">Duggan 2001</LINK>) will contain data relating to studies with mixed populations of mentally ill and not ill, and, if possible, this review will incorporate data from the younger age range. One included study, (<LINK REF="STD-McKenzie-1966" TYPE="STUDY">McKenzie 1966</LINK>) that did not allow extraction of data relating only to adults without mental illness, stated that the young and mentally ill had a systematically different outcome to those solely with learning disability and challenging behaviour. Nevertheless very many adults with learning disability and challenging behaviour, who have no discernible mental illness are treated with these powerful drugs.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-11 15:16:34 +0000" MODIFIED_BY="Cathy Bennett">
<IMPLICATIONS_PRACTICE MODIFIED="2008-11-11 15:16:06 +0000" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="3">For those caring for, or with learning disability and challenging behaviour</HEADING>
<P>If possible, carers or recipients of care should be made aware of the paucity of evidence for the efficacy of this treatment. The lack of evidence of efficacy combined with the likely prevalence of adverse effects, especially in the longer term, may affect a person's willingness to take antipsychotic medication or the ease with which a carer is persuaded to administer them.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">For managers and policy makers</HEADING>
<P>Many people with challenging behaviour have been reprovided for in the community following the closure of the old learning disability hospitals. They often have remained on antipsychotic medication. Management of this large vulnerable group is based on non-randomised trial evidence. This may come as a surprise to the powerful consumer lobby groups associated with those with learning disability. In turn, this may encourage managers and policy makers to insist on good research before implementing guidelines that may do more harm than good.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">For clinicians</HEADING>
<P>Without randomised controlled trial-based evidence, clinicians will have to continue to base practice on clinical experience and humane judgement. It is debatable whether use of antipsychotic medication for certain people with learning disability and challenging behaviour is ethical outside of a randomised controlled trial. Evaluation of these treatments requires urgent attention; until then, clinical practice in relation to this vulnerable group will be based on opinion, judgement and fashion rather than evidence.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-11-11 15:16:34 +0000" MODIFIED_BY="Cathy Bennett">
<P>There is an urgent need for randomised controlled trials of the efficacy of antipsychotic medication in the treatment of adults with learning disability and challenging behaviour.</P>
<P>This research should describe: </P>
<OL>
<LI>the randomization procedure, blinding and details of those leaving the study early;</LI>
<LI>the participants with respect of demographic details;</LI>
<LI>the challenging behaviour and secondary outcomes in clear terms, over both in the short-term and long-term.</LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Leanne Roberts and Clive Adams of the Cochrane Schizophrenia Group for constant and patient support amidst adversity. The pharmacy staff at Fair Mile Hospital for identifying non-BNF antipsychotics.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Jane Brylewski - has received an honorarium from Janssen for speaking at a conference.</P>
<P>Lorna Duggan - has attended functions sponsored by Lundbeck, Janssen, Pfizer and Zeneca, has received honoraria from Janssen for speaking at conferences and has accepted sponsorship from Eli Lilly for internal flights in the United States.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Jane Brylewski and Lorna Duggan contributed equally to the work of protocol writing, search strategy formulation, data entry, statistical analysis and report writing.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-11 20:39:54 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-11-11 20:35:30 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Albert-1977" NAME="Albert 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albert JM, Elie R, Cooper SF, Clermont A, Langlois Y</AU>
<TI>Efficacy of SCH-12679 in the management of aggressive mental retardates</TI>
<SO>Current Therapeutic Research</SO>
<YR>1977</YR>
<VL>21</VL>
<PG>786-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Cuyper-1985" NAME="De Cuyper 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Cuyper H, van Praag HM, Verstraeten D</AU>
<TI>The effect of milenperone on the aggressive behavior of oligophrenic patients. A double-blind placebo-controlled study</TI>
<SO>Neuropsychobiology</SO>
<YR>1985</YR>
<VL>13</VL>
<PG>101-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Koning-1994" NAME="de Koning 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Koning P, Mak M, de Vries MH, Allsop LF and the Eltoprazine Aggression Research Group</AU>
<TI>Eltoprazine in aggressive mentally handicapped patients: a double-blind, placebo- and baseline-controlled multi-centre study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>187-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elie-1980" NAME="Elie 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elie R, Langlois Y, Cooper SF, Gravel G, Albert J-M</AU>
<TI>Comparison of SCH-12679 and thioridazine in aggressive mental retardates</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>25</VL>
<PG>484-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lynch-1985" NAME="Lynch 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lynch DM, Eliatamby CLS, Anderson AA</AU>
<TI>Pipothiazine palmitate in the management of aggressive mentally handicapped patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1985</YR>
<VL>146</VL>
<PG>525-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDougle-1998" NAME="McDougle 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH</AU>
<TI>A double-blind, placebo-controlled study of risperidone in adults with autistic disorders and other pervasive developmental disorders</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1998</YR>
<VL>55(7)</VL>
<PG>663-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKenzie-1966" NAME="McKenzie 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McKenzie ME, Roswell-Harris D</AU>
<TI>A controlled trial of Prothipendyl (Tolnate) in mentally subnormal patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1966</YR>
<VL>112</VL>
<PG>95-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Hemert-1975" NAME="van Hemert 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Hemert JCJ</AU>
<TI>Pipamperone (dipiperon, R3345) in troublesome mental retardates: a double-blind placebo controlled cross-over study with long-term follow-up</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1975</YR>
<VL>52</VL>
<PG>237-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zwanikken-1973" NAME="Zwanikken 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zwanikken GJ</AU>
<TI>Penfluridol (R 16341). A long-acting oral neuroleptic, as maintainance therapy for schizophrenic and mentally retarded patients</TI>
<SO>Psychiatria, Neurologia, Neurochirurgia</SO>
<YR>1973</YR>
<VL>76</VL>
<PG>83-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-11 20:35:30 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ahmed-2000" NAME="Ahmed 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ahmed Z, Fraser W, Kerr MP, Kiernan C, Emerson E, Robertson J, Felce D, Allen D, Baxter H, Thomas J</AU>
<TI>Reducing antipsychotic medication in people with a learning disability</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Al-Kaisi-1974" NAME="Al Kaisi 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Kaisi AH, McGuire RJ</AU>
<TI>The effect of sulthiame on disturbed behavior in mentally subnormal patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1974</YR>
<VL>124</VL>
<PG>45-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aman-1989" NAME="Aman 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aman MG, Teehan CJ, White TJ, Turbott SH, Vaithianathan C</AU>
<TI>Haloperidol treatment with chronically medicated residents: dose effects on clinical behavior and reinforcement contingencies</TI>
<SO>American Journal on Mental Retardation</SO>
<YR>1989</YR>
<VL>93</VL>
<PG>452-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aman-1999" NAME="Aman 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aman MG, Madrid A</AU>
<TI>Atypical antipsychotics in persons with developmental disabilities</TI>
<SO>Mental Retardation and Developmental Disabilities Research Reviews</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>4</NO>
<PG>253-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barnard-2002" NAME="Barnard 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;           .&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnard L, Young A H, Pearson J, Geddes J, O'Brien G</AU>
<TI>A systematic review of the use of atypical antipsychotics in autism</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2002</YR>
<VL>16 (1)</VL>
<PG>93-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buitelaar-2001" NAME="Buitelaar 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buitelaar J,van der Gaag RJ, Cohen-Kettenis P, Melman CTM</AU>
<TI>A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62 (4)</VL>
<PG>239-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Buitelaar JK, van der Gaag RJ, Melman CTM</AU>
<TI>Risperidone in the treatment of aggressive behaviour disorders in adolescents with mild mental retardation. A prospective, randomised, double-blind, placebo-controlled trial</TI>
<SO>11th European College of Neuropsychopharmacology Congress. Paris, France. 31st October - 4th November 1998 PG:Abstract:</SO>
<YR>1998</YR>
<PG>P.6.009.</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burk-1968" NAME="Burk 1968" YEAR="1968">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burk HW, Menolascino FJ</AU>
<TI>Haloperidol in emotionally disturbed mentally retarded individuals</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1968</YR>
<VL>124(11)</VL>
<PG>1589-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1969" NAME="Davis 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis KV, Sprague RL, Werry JS</AU>
<TI>Stereotyped behavior and activity level in severe retardates: the effect of drugs</TI>
<SO>American Journal of Mental Deficiency</SO>
<YR>1969</YR>
<VL>73(5)</VL>
<PG>721-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hacke-1978" MODIFIED="2008-11-11 20:35:30 +0000" MODIFIED_BY="[Empty name]" NAME="Hacke 1978" YEAR="1978">
<REFERENCE MODIFIED="2008-11-11 20:35:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hacke W, Bussing A, Jungen K</AU>
<TI>The effects of Methylperon (Eunerpan) on aggressive and auto-aggressive behavior in mentally retarded patients - A double- blind study</TI>
<TO>Die wirkung von methylperon (eunerpan) auf aggressives und auto-aggressives verhalten bei geistigbehinderten. Eine doppelblindstudie [German]</TO>
<SO>Pharmakopsychiatrie Neuropsychopharmakologie</SO>
<YR>1978</YR>
<VL>11</VL>
<PG>86-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hammock-1995" NAME="Hammock 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hammock RG, Schroeder SR, Levine WR</AU>
<TI>The effect of clozapine on self-injurious behavior</TI>
<SO>Journal of Autism and Developmental Disorders</SO>
<YR>1995</YR>
<VL>25</VL>
<PG>611-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heistad-1979" NAME="Heistad 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heistad GT, Zimmermann RL</AU>
<TI>Double-blind assessment of mellarill in a mentally retarded population using detailed evaluations</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1979</YR>
<VL>15</VL>
<NO>2</NO>
<PG>86-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Izmeth-1988" NAME="Izmeth 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Izmeth GA, Khan SY, Kumarajweewa DISC, Shivanathan S, Veall RM, Wiley YV</AU>
<TI>Zuclopenthixol decanoate in the management of behavioural disorders in mentally handicapped patients</TI>
<SO>Pharmatherapeutica</SO>
<YR>1988</YR>
<VL>5</VL>
<PG>217-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karsten-1981" NAME="Karsten 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karsten D, Kivimaki T, Linna SL, Pollari L, Turunen S</AU>
<TI>Neuroleptic treatment of oligophrenic patients</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1981</YR>
<VL>294</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindholm-1967" NAME="Lindholm 1967" YEAR="1967">
<REFERENCE NOTES="&lt;p&gt;Lindholm O. A clinical study of esucos in a mentally retarded clientelle. International Journal of Neuropsychiatry 1967;3:209-18.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindholm O</AU>
<TI>A clinical study of esucos in a mentally retarded clientele</TI>
<SO>International Journal of Neuropsychiatry</SO>
<YR>1967</YR>
<VL>3</VL>
<PG>209-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mace-2001" NAME="Mace 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mace FC, Blum NJ, Sierp BJ, Delaney BA, Mauk JE</AU>
<TI>Differential response of operant self-injury to pharmacologic versus behavioral treatment.</TI>
<SO>Journal of Developmental &amp; Behavioral Pediatrics</SO>
<YR>2001</YR>
<VL>22(2)</VL>
<PG>85-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McConahey-1971" NAME="McConahey 1971" YEAR="1971">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McConahey OL, Thompson T</AU>
<TI>Concurrent behavior modification and chlorpromazine therapy in a population of institutionalized mentally retarded women</TI>
<SO>Proceedings of the Annual Convention of the American Psychological Association</SO>
<YR>1971</YR>
<VL>6(Pt. 2)</VL>
<PG>761-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millichamp-1987" NAME="Millichamp 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millichamp CJ, Singh NN</AU>
<TI>The effects of intermittent drug therapy on stereotypy and collateral behaviors of mentally retarded persons</TI>
<SO>Research in Developmental Disabilities</SO>
<YR>1987</YR>
<VL>8</VL>
<PG>213-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nielsen-1967" NAME="Nielsen 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen B</AU>
<TI>Oligofrene patienter behandlet med flupentixol</TI>
<SO>Nordisk Psykiatrisk Tidsskrift</SO>
<YR>1967</YR>
<VL>21</VL>
<PG>244-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Remington-2001" NAME="Remington 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Remington G, Sloman L, Konstantareas M, Parker K, Gow R</AU>
<TI>Clomipramine versus haloperidol in the treatment of autistic disorder: A double-blind, placebo-controlled, crossover study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>21(4)</VL>
<PG>440-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schroeder-1995" NAME="Schroeder 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schroeder SR, Hammock RG, Mulick JA, Rojahn J, Walson P, Fernald W, Meinhold P,Saphare G</AU>
<TI>Clinical trials of D-sub-1 and D- sub-2 dopamine modulating drugs and self injury in mental retardation and developmental disability</TI>
<SO>Mental Retardation and Developmental Disabilities Research Reviews</SO>
<YR>1995</YR>
<VL>1</VL>
<NO>2</NO>
<PG>120-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sime-1974" NAME="Sime 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sime DA, Easby FPD</AU>
<TI>A double-blind cross-over study of the effect of beclamide (nydrane) on behaviour disorders in the severely mentally handicapped</TI>
<SO>British Journal of Mental Subnormality</SO>
<YR>1974</YR>
<VL>20</VL>
<PG>90-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1981" NAME="Singh 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh NN, Aman MG</AU>
<TI>Effects of thioridazine dosage on the behavior of severely mentally retarded persons</TI>
<SO>American Journal of Mental Deficiency</SO>
<YR>1981</YR>
<VL>85</VL>
<PG>580-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1992" NAME="Singh 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh I, Owino WJE</AU>
<TI>A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural disorders</TI>
<SO>Journal of Intellectual Disability Research</SO>
<YR>1992</YR>
<VL>36</VL>
<PG>541-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaisanen-1975" NAME="Vaisanen 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaisanen K, Kainulainen P, Paavilainen MT, Viukari M</AU>
<TI>Sulpiride versus chlorpromazine and placebo in the treatment of restless mentally subnormal patients - a double-blind cross-over study</TI>
<SO>Current Theraputic Research</SO>
<YR>1975</YR>
<VL>17</VL>
<PG>202-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaisanen-1979" NAME="Vaisanen 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaisanen K, Rimon R, Raisanen P, Viukari M</AU>
<TI>A controlled double-blind study of haloperidol versus thioridazine in the treatment of restless mentally subnormal patients. Serum levels and clinical effects</TI>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1979</YR>
<VL>79</VL>
<PG>673-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaisanen K, Viukari M, Rimon R, Raisanen P</AU>
<TI>Haloperidol, thioridazine and placebo in mentally subnormal patients - serum levels and clinical effects</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1981</YR>
<VL>63</VL>
<PG>262-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanden-Borre-1993" NAME="Vanden Borre 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanden Borre R, Vermote R, Buttiens M, Thiry P, Dierick G, Geujens J, Sieben G, Heylen S</AU>
<TI>Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo cross-over study</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>87</VL>
<PG>167-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wardell-1958" NAME="Wardell 1958" YEAR="1958">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wardell D</AU>
<TI>The use of reserpine and chlorpromazine in disturbed mentally deficient patients</TI>
<SO>American Journal of Mental Deficiency</SO>
<YR>1958</YR>
<VL>63</VL>
<PG>330-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weir-1968" NAME="Weir 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacKay DN</AU>
<TI>Evaluation of tranquilisers with subnormal patients. 2. pericyazine and chlorpromazine</TI>
<SO>Nursing Mirror</SO>
<YR>1971</YR>
<VL>6 August</VL>
<PG>2-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weir TWH, Kernohan GA, MacKay DN</AU>
<TI>The use of pericyazine and chlorpromazine with disturbed mentally subnormal patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1968</YR>
<VL>114</VL>
<PG>111-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1985" NAME="White 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White TJR, Aman MG</AU>
<TI>Pimozide treatment in disruptive severely retarded patients</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>19</VL>
<PG>92-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-2000" NAME="Williams 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams H, Clarke R, Bouras N, Martin J, Holt G</AU>
<TI>Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability</TI>
<SO>Journal of Intellectual Disability Research</SO>
<YR>2000</YR>
<VL>44</VL>
<NO>2</NO>
<PG>164-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wright-1993" NAME="Wright 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Wright EC</AU>
<TI>Drug control of behaviour. A study of the effects of thioridazine and haloperidol in adults with severe learning disabilities [dissertation]</TI>
<SO>University of London,</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zarcone-2002" NAME="Zarcone 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zarcone JR, Hellings JA, Crandall K, Reese RM, Marquis J, Fleming K, Shores R, Williams D and Schroeder SR</AU>
<TI>Effects of Risperidone on Aberrant Behavior of Persons With Developmental Disabilities: I. A Double-Blind Crossover Study Using Multiple Measures</TI>
<SO>American Journal on Mental Retardation</SO>
<YR>2002</YR>
<VL>106</VL>
<NO>6</NO>
<PG>525-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zimmermann-1982" NAME="Zimmermann 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zimmermann RL, Heistad GT</AU>
<TI>Studies of the long term efficacy of antipsychotic drugs in controlling the behavior of institutionalized retardates</TI>
<SO>Journal of the American Academy of Child Psychiatry</SO>
<YR>1982</YR>
<VL>21</VL>
<PG>136-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipman-1981" NAME="Lipman 1981" YEAR="1981">
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-11 20:39:54 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-11 20:39:54 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aman-1984" MODIFIED="2008-11-11 20:38:40 +0000" MODIFIED_BY="[Empty name]" NAME="Aman 1984" TYPE="BOOK_SECTION">
<AU>Aman MG</AU>
<TI>Drugs and learning in mentally retarded persons</TI>
<SO>Advances in Human Psychopharmacology</SO>
<YR>1984</YR>
<ED>Burrows GD, Werry JS</ED>
<PB>JAI Press</PB>
<CY>Greenwich, CT, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aman-1986" NAME="Aman 1986" TYPE="BOOK">
<AU>Aman MG, Singh NN</AU>
<SO>The Aberrant Behavior Checklist</SO>
<YR>1986</YR>
<PB>Slosson Educational Publications</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA--1994" MODIFIED="2008-11-11 20:39:54 +0000" MODIFIED_BY="[Empty name]" NAME="APA  1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)</SO>
<YR>1994</YR>
<VL>4th</VL>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bair-1955" NAME="Bair 1955" TYPE="JOURNAL_ARTICLE">
<AU>Bair HV, Herold W</AU>
<TI>Efficacy of chlorpromazine in hyperactive mentally retarded children</TI>
<SO>Archives of Neurology and Psychiatry</SO>
<YR>1955</YR>
<VL>74</VL>
<PG>363-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BNF-2001" NAME="BNF 2001" TYPE="BOOK">
<AU>British Medical Association and Royal Pharmaceutical Society of Great Britain</AU>
<SO>British National Formulary</SO>
<YR>2001</YR>
<VL>41</VL>
<PB>Pharmaceutical Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Capes-1970" NAME="Capes 1970" TYPE="JOURNAL_ARTICLE">
<AU>Capes L, Moore BC</AU>
<TI>Behavior differences between seizure and non-seizure retardates</TI>
<SO>Arizona Medicine</SO>
<YR>1970</YR>
<VL>27</VL>
<PG>74-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2001" MODIFIED="2008-11-11 20:29:02 +0000" MODIFIED_BY="[Empty name]" NAME="Clarke 2001" TYPE="BOOK_SECTION">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>6.7.1 Cochrane Reviewers Handbook Approaches to summarising the validity of studies</TI>
<SO>The Cochrane Library</SO>
<YR>March 2001</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deb-1991" NAME="Deb 1991" TYPE="JOURNAL_ARTICLE">
<AU>Deb S, Hunter D</AU>
<TI>Psychopathology of people with mental handicap and epilepsy. 1: Maladaptive behaviour</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1991</YR>
<VL>159</VL>
<PG>822-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2001" MODIFIED="2008-11-11 20:32:28 +0000" MODIFIED_BY="[Empty name]" NAME="Duggan 2001" TYPE="OTHER">
<AU>Duggan L, Brylewski J</AU>
<TI>Antipsychotics, learning disability and schizophrenia (Cochrane Schizophrenia Group module)</TI>
<SO>The Cochrane Library</SO>
<YR>2001</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Emerson-1995" MODIFIED="2008-11-11 20:28:38 +0000" MODIFIED_BY="[Empty name]" NAME="Emerson 1995" TYPE="BOOK_SECTION">
<AU>Emerson C</AU>
<TI>Introduction</TI>
<SO>Challenging behaviour: Analysis and intervention in people with learning difficulties</SO>
<YR>1995</YR>
<PB>Cambridge University Press</PB>
<CY>Cambridge</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ERAG-1992" MODIFIED="2008-11-11 20:28:33 +0000" MODIFIED_BY="[Empty name]" NAME="ERAG 1992" TYPE="JOURNAL_ARTICLE">
<AU>European Rating Aggression Group (ERAG)</AU>
<TI>Social Dysfunction and Aggression Scale (SDAS-21) in generalized aggression and in aggressive attacks: a validity and reliability study</TI>
<SO>International Journal of Methods in Psychiatric Research</SO>
<YR>1992</YR>
<VL>2</VL>
<PG>15-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eyman-1969" NAME="Eyman 1969" TYPE="JOURNAL_ARTICLE">
<AU>Eyman RK, Moore BC, Capes L, Zachofsky T</AU>
<TI>Maladaptive behavior of institutionalized retardates with seizures</TI>
<SO>American Journal of Mental Deficiency</SO>
<YR>1969</YR>
<VL>74</VL>
<PG>651-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freeman-1986" NAME="Freeman 1986" TYPE="JOURNAL_ARTICLE">
<AU>Freeman BJ, Ritvo ER, Yokata A, Ritvo A</AU>
<TI>A scale for rating symptoms of patients with the syndrome of autism in real life settings</TI>
<SO>Journal of the American Academy of Child and Adolescent Psychiatry</SO>
<YR>1986</YR>
<VL>25</VL>
<PG>130-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gingell-1994" NAME="Gingell 1994" TYPE="JOURNAL_ARTICLE">
<AU>Gingell K, Nadarajah J</AU>
<TI>A controlled community study of movement disorder in people with learning difficulties on antipsychotic medication</TI>
<SO>Journal of Intellectual Disability Research</SO>
<YR>1994</YR>
<VL>37</VL>
<PG>53-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2008-11-11 20:31:44 +0000" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<PB>U.S. National Institute of Health, Psychopharmacology Research Branch</PB>
<CY>Rockville MD</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Publication No.76-338."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harris-1993" NAME="Harris 1993" TYPE="JOURNAL_ARTICLE">
<AU>Harris P</AU>
<TI>The nature and extent of aggressive behaviour amongst people with learning difficulties (mental handicap) in a single health district</TI>
<SO>Journal of Intellectual Disability Research</SO>
<YR>1993</YR>
<VL>37</VL>
<PG>221-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Linaker-1990" MODIFIED="2008-11-11 14:39:41 +0000" MODIFIED_BY="[Empty name]" NAME="Linaker 1990" TYPE="JOURNAL_ARTICLE">
<AU>Linaker OM</AU>
<TI>Frequency and determinants for psychotropic drug use in an institution for the mentally retarded</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>156</VL>
<PG>525-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manchester-1993" MODIFIED="2008-11-11 14:39:41 +0000" MODIFIED_BY="[Empty name]" NAME="Manchester 1993" TYPE="JOURNAL_ARTICLE">
<AU>Manchester D</AU>
<TI>Neuroleptics, learning disability, and the community: some history and mystery</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>307</VL>
<PG>184-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nihira-1993" MODIFIED="2008-11-11 14:39:41 +0000" MODIFIED_BY="[Empty name]" NAME="Nihira 1993" TYPE="BOOK">
<AU>Nihira K, Leland H, Lambert N</AU>
<TI>ABS - Adaptive Behavior Scale DISCUS - Dyskinesia Identification System: Condensed User Scale</TI>
<SO>AAMR Adaptive Behavior Scale - Residential and Community</SO>
<YR>1993</YR>
<EN>2nd</EN>
<PB>Pro-Ed</PB>
<CY>Austin, Texas</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oliver-1987" MODIFIED="2008-11-11 14:39:41 +0000" MODIFIED_BY="[Empty name]" NAME="Oliver 1987" TYPE="JOURNAL_ARTICLE">
<AU>Oliver C, Murphy GH, Corbett JA</AU>
<TI>Self-injurious behaviour in people with mental handicap: a total population study</TI>
<SO>Journal of Mental Deficiency Research</SO>
<YR>1987</YR>
<VL>31</VL>
<PG>147-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rinck-1989" MODIFIED="2008-11-11 14:39:41 +0000" MODIFIED_BY="[Empty name]" NAME="Rinck 1989" NOTES="&lt;p&gt;Rinck C, Guidry J, Calkins CF. Review of states' pracice on the use of psychotropic medication. American Journal of Mental Retardation 1989;93:657-68.&lt;/p&gt;" NOTES_MODIFIED="2008-11-11 14:39:41 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Rinck C, Guidry J, Calkins CF</AU>
<TI>Review of states' practice on the use of psychotropic medication</TI>
<SO>American Journal of Mental Retardation</SO>
<YR>1989</YR>
<VL>93</VL>
<PG>657-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rogers-1991" MODIFIED="2008-11-11 14:39:41 +0000" MODIFIED_BY="[Empty name]" NAME="Rogers 1991" TYPE="JOURNAL_ARTICLE">
<AU>Rogers D, Karki C, Bartlett C, Pocock P</AU>
<TI>The motor disorders of mental handicap. An overlap with the motor disorders of severe psychiatric illness</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1991</YR>
<VL>158</VL>
<PG>97-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sachdev-1992" MODIFIED="2008-11-11 14:39:41 +0000" MODIFIED_BY="[Empty name]" NAME="Sachdev 1992" NOTES="&lt;p&gt;Sachdev P. Drug induced movement disorders in institutionalised adults with mental retardation. Clinical characteristics and risk factors. Australian and New Zealand Journal of Psychiatry 1992;26:242-8.&lt;/p&gt;" NOTES_MODIFIED="2008-11-11 14:39:41 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Sachdev P</AU>
<TI>Drug induced movement disorders in institutionalised adults with mental retardation: clinical characteristics and risk factors</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>26</VL>
<PG>242-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schaal-1994" MODIFIED="2008-11-11 20:38:47 +0000" MODIFIED_BY="[Empty name]" NAME="Schaal 1994" TYPE="JOURNAL_ARTICLE">
<AU>Schaal DW, Hackenburg T</AU>
<TI>Toward a functional analysis of drug treatment for behavior problems of people with developmental disabilities</TI>
<SO>Mental Retardation</SO>
<YR>1994</YR>
<VL>92</VL>
<NO>2</NO>
<PG>123-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sprague-1989" MODIFIED="2008-11-11 14:39:41 +0000" MODIFIED_BY="[Empty name]" NAME="Sprague 1989" TYPE="JOURNAL_ARTICLE">
<AU>Sprague RL, Kalachnik JE, Shaw KM</AU>
<TI>Psychometric properties of the Dyskinesia Identification System: Condensed User Scale (DISCUS)</TI>
<SO>Mental Retardation</SO>
<YR>1989</YR>
<VL>27</VL>
<PG>141-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1991" MODIFIED="2008-11-11 20:38:45 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 1991" TYPE="BOOK">
<AU>WHO Scientific Group on Treatment of Psychiatric Disorders</AU>
<SO>Evaluation of methods for the treatment of mental disorders</SO>
<YR>1991</YR>
<PB>World Health Organisation</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1992" MODIFIED="2008-11-11 14:39:41 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 1992" TYPE="BOOK">
<AU>World Health Organisation</AU>
<SO>International Classification of Disease and related disorders (ICD-10)</SO>
<YR>1992</YR>
<PB>World Health Organisation</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Youseff-1988" MODIFIED="2008-11-11 14:39:41 +0000" MODIFIED_BY="[Empty name]" NAME="Youseff 1988" TYPE="JOURNAL_ARTICLE">
<AU>Youseff HA, Waddington JL</AU>
<TI>Involuntary orofacial movements in hospitalised patients with mental handicap or epilepsy; relationship to developmental/ intellectual deficit and presence or absence of long term exposure to neuroleptics</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1988</YR>
<VL>51</VL>
<PG>863-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yudofsky-1986" MODIFIED="2008-11-11 20:38:50 +0000" MODIFIED_BY="[Empty name]" NAME="Yudofsky 1986" TYPE="JOURNAL_ARTICLE">
<AU>Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D</AU>
<TI>The Overt Aggression Scale for the objective rating of verbal and physical aggression</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>143</VL>
<PG>33-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-11 15:25:59 +0000" MODIFIED_BY="Cathy Bennett">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-11 15:24:38 +0000" MODIFIED_BY="Cathy Bennett" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-11 15:24:03 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Albert-1977">
<CHAR_METHODS MODIFIED="2008-11-11 15:24:03 +0000" MODIFIED_BY="Cathy Bennett">
<P>Allocation: randomised, no further details.<BR/>Blindness: double - identical capsules.<BR/>Duration: 28 days (preceded by 4/52 of chlorpromazine 300mg/day).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: profoundly mentally retarded, schizophrenia excluded.<BR/>History: aggressive. <BR/>Setting: in-patients, one centre. <BR/>N=18.<BR/>Age: adult.<BR/>Sex: 18 F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. SCH-12679: dose 100mgs four times daily. N=9.<BR/>2. Placebo: dose four times daily. N=9.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Unable to use - <BR/>Global impression (GIS, no SD).<BR/>Aggression (TSA, no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>One person in active drug group left study due to epileptic seizure.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-De-Cuyper-1985">
<CHAR_METHODS>
<P>Allocation: randomised, not further described.<BR/>Blindness: double-blind, not further described.<BR/>Duration: 6 weeks.</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: oligophrenia.<BR/>21 female, adult, inpatients, 3 of whom had a psychotic illness. Mean age 48 years (range 26-76). Chronic aggressive behaviour manifesting as negativism, dysphoria, verbal and/or psychomotor excitation with destructive behaviour towards patients, nurses or material.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Milenperone: dose 10mg twice daily. N=10.<BR/>2. Placebo: dose twice daily. N=11.<BR/>Similar presentation (drops) of both compounds.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Paranoid Belligerence Scale (subscale of the Psychotic Reaction Profile measuring antisocial behaviour).<BR/>2. Visual analogue scale, measuring a single target behaviour for each participant.<BR/>3. Side effects scored by a psychiatrist on a four-point scale.<BR/>4. Blood examination.</P>
<P>Unable to extract data for those with learning disability without psychosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-11 15:24:09 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-de-Koning-1994">
<CHAR_METHODS MODIFIED="2008-11-11 15:24:09 +0000" MODIFIED_BY="Cathy Bennett">
<P>Allocation: randomised ratio of 3:1, no further details.<BR/>Blindness: double-blind.<BR/>Duration: 8 weeks, preceded by 4 week baseline period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: mental retardation (DSM-III-R)*.<BR/>History: destructive behaviour, verbal / physical aggression &gt; 4 times / week, in-patients for &gt; 1 month.<BR/>N=160.<BR/>Sex: 99 M, 61 F.<BR/>Age: adults, 18-65 years.<BR/>Setting: multicentre, Europe.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Eltoprazine: dose 10mgs twice daily. N=119.<BR/>2. Placebo: dose twice daily. N=41.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Behaviour - aggression (OAS, SDAS).<BR/>Behaviour - non-specific.<BR/>Side-effects.<BR/>Unable to use -<BR/>Aggression (GAS, not peer reviewed scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*A co-existing diagnosis of pervasive developmental disorder was allowed but other axis I or II diagnoses requiring psychotropic medication were not.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Elie-1980">
<CHAR_METHODS>
<P>Allocation: randomised, stratified for gender and epilepsy status. Not further described.<BR/>Blindness: double-blind, not further described.<BR/>Duration: 4 weeks following a 3 week drug standardisation period when chlorpromazine 100mg three times daily was substituted for other antipsychotic medication.</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: "mentally retarded" . <BR/>History: aggressive behaviour unmanageable without physical restraints or confinement. In-patients, <BR/>Excluded if suffering from schizophrenia, cardiac, renal, hepatic or metabolic abnormalities. 29 suffered from epilepsy. <BR/>N=51.<BR/>Sex: 33 men,18 women.<BR/>Age: mean 32.9 years (2.51 SD).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. SCH-12679: 100mg. <BR/>2. Thioridazine: 50mg.<BR/>3. Placebo:<BR/>Identical presentation, given four times a day.<BR/>Numbers randomised to each group not described.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Target Symptom Aggressivity Scale.<BR/>2. Clinical Global Impression Scale.<BR/>3. Chief Aggressive Manifestations.<BR/>4. Blood analysis.<BR/>5. Urinanalysis.</P>
<P>Unable to extract any data as the numbers randomised to each condition is not described.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-11 15:24:13 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Lynch-1985">
<CHAR_METHODS MODIFIED="2008-11-11 15:24:10 +0000" MODIFIED_BY="Cathy Bennett">
<P>Allocation: randomised, no further details.<BR/>Blindness: double-blind, not further described.<BR/>Design: crossover.<BR/>Duration: 13 weeks (proceeded by a four week wash-out period).</P>
<P>.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-11 15:24:13 +0000" MODIFIED_BY="Cathy Bennett">
<P>Diagnosis: "mentally handicapped".<BR/>History: aggressive or difficult to manage, in-patients.<BR/>Excluded if symptoms or signs of schizophrenia, psychomotor epilepsy, renal dysfunction, heart disease, pregnancy or risk of pregnancy.<BR/>N=30<BR/>Sex: 21 male, 9 female.<BR/>Age: mean 37.1 years (12.1 SD).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Pipothiazine palmitate: 50mg, intramuscular injection.<BR/>2. Placebo: intramuscular injection.<BR/>Every four weeks.<BR/>Crossover after 13 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Unable to extract any data from the paper, for the first arm of the trial.<BR/>1. Leaving the study early.<BR/>2. Clinical Global Impression Scale.<BR/>3. Target Symptom Aggressivity Scale.<BR/>4. Weekly consensus clinical outcome.<BR/>5. Side effects - clinical assessments weekly.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-11 15:24:20 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-McDougle-1998">
<CHAR_METHODS MODIFIED="2008-11-11 15:24:17 +0000" MODIFIED_BY="Cathy Bennett">
<P>Allocation: randomised, computer generated, no further details.<BR/>Blindnes: double-blind, identical-appearing capsules.<BR/>Duration: 12 weeks (proceeded by a one month washout period where psychotropics were stopped). 12 week open-label extension of risperidone given to placebo group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-11 15:24:20 +0000" MODIFIED_BY="Cathy Bennett">
<P>Diagnosis: adults with autism or pervasive<BR/>developmental disorder not otherwise specified (DSM-IV).<BR/>History: at least "moderate" severity on Clinical Global Impression. Y-BOCS (compulsion subscale &gt;10), SIB-Q &gt;24 or a Ritvo-Freeman Real-life Rating Scale overall score &gt; 0.20.<BR/>Excluded if met DSM-IV criteria for schizophrenia or had psychotic symptoms or if a significant acute medical condition was identified.<BR/>N=31<BR/>Age: 18-43, mean 28.1<BR/>Sex: 9 women, 22 men. 7 participants were not mentally retarded.<BR/>Location: 24 outpatients, 7 inpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Risperidone: commenced on 1mg/day increased up to 10mg/day. N=15.<BR/>2. Placebo: 1mg/day increased to maximum of 10mg/day. N=16.<BR/>Identical capsules given at night.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Leaving the study early.<BR/>2. Clinical Global Impression. <BR/>3. Ritvo-Freeman Real-life Rating Scale.<BR/>4. Physiological measures (sitting and standing blood pressure, pulse rate and weight).<BR/>5. Examination for extrapyramidal and other adverse effects.<BR/>Unable to use - Y-BOCS, (no data reported), SIB-Q (not a validated scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-11 15:24:20 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-McKenzie-1966">
<CHAR_METHODS MODIFIED="2008-11-11 15:24:20 +0000" MODIFIED_BY="Cathy Bennett">
<P>Allocation: randomised by chief pharmacist, no further details.<BR/>Blinding: double-blind.<BR/>Duration: 16 weeks (proceeded by a one month washout period where antipsychotics were stopped).<BR/>.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: "severely subnormal".<BR/>History: in-patients with long-standing behaviour disorders. Four had schizophrenia.<BR/>N=40.<BR/>Sex: 20 males, 20 females.<BR/>Age: males 16-31 (mean 20 years 6 months), females 14-42 (mean 26 years 2 months).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Prothipendyl: 80mg tablets (range 360-1280mg per day in males, 480-960mg per day in females). N=20.<BR/>2. Placebo: N=19.</P>
<P>
<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Data could not be extracted for adults without schizophrenia. </P>
<P>1. Psychological investigations - Goodenough "Draw a man" and Seguin Form Board.<BR/>2. Claridge excitability Rating scale.<BR/>3. Clinical assessment.<BR/>4. Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-11 15:24:35 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-van-Hemert-1975">
<CHAR_METHODS MODIFIED="2008-11-11 15:24:20 +0000" MODIFIED_BY="Cathy Bennett">
<P>Allocation: randomised, no further details.<BR/>Blindness: double.<BR/>Design: crossover X 1.<BR/>Duration: 3 weeks (proceeded by 2 week placebo washout).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-11 15:24:35 +0000" MODIFIED_BY="Cathy Bennett">
<P>Diagnosis: mental retardation - moderate (9), severe (10), profound (1) (DSM-II).<BR/>History: "strong aggressiveness and other troublesome behaviour", in patients.<BR/>N=20.<BR/>Sex: 20 F.<BR/>Age: range 22-42, median 33 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Pipamperone (Dipiperon, R3345): dose 80 - 240 mg / day. N=10.<BR/>2. Placebo: tablet frequency as in group 1. N=10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Unable to use - <BR/>Behaviour (not peer reviewed scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-11 15:24:38 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Zwanikken-1973">
<CHAR_METHODS>
<P>Allocation: randomised, not further described.<BR/>Blindness: double-blind, not further described.<BR/>Design: stage I - 4 weeks - neuroleptic withdrawal and replacement with increasing doses of penfluridol; stage II - 2 months - open assessment of efficacy of maintenance dose of penfluridol; stage II - 6 months - double-blind study of penfluridol versus placebo.</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-11 15:24:38 +0000" MODIFIED_BY="Cathy Bennett">
<P>Diagnosis: "mentally retarded" in-patients with and without schizophrenia and "non retarded" with schizophrenia.<BR/>History: long-term in-patients on maintenance with haloperidol. Excluded if exhibiting aggression or agitation during the month preceding the start of the trial.<BR/>N=48.<BR/>Sex: not described.<BR/>Age: schizophrenics range 25-74 years (median 55) and mentally retarded 22-67 years (median 40 ).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Penfluridol: N=20.<BR/>2. Placebo: N=17.<BR/>Identical tablets.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Data for those with learning disability without a superimposed mental illness could not be extracted. Reviewers contacted Professor Zwanikken who could not clarify the data.</P>
<P>1. Rating Scale previously described by the author.<BR/>2. Clinical interview.<BR/>3. Nursing score - including side effects.<BR/>4. Use of additional haloperidol.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>General<BR/>DSM-II - Diagnostic Statistical Manual 2nd version.<BR/>DSM-IV - Diagnostic Statistical Manual 4th version.<BR/>Y-BOCS - Yale-Brown Obsessive Compulsive Scale.</P>
<P>SCALES<BR/>GAS - Global Aggression Scale (a measure of severity of aggressive episodes).<BR/>GIS - Global Impression Scale (clinical assessment of condition and severity of side effects). <BR/>OAS - Overt Aggression Scale (a measure of frequency and severity of aggressive episodes).<BR/>SDAS - Social Dysfunction and Aggression Scale (a measure of clinical or psychopathological aggression).<BR/>TSA - Target Symptom Aggressivity Scale.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-11 15:25:59 +0000" MODIFIED_BY="Cathy Bennett" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ahmed-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: adults, behavioural problems, not psychotic, hospital or community.<BR/>Interventions: 4 monthly drug reduction stages of 25%.<BR/>Outcomes: ABS, ABC, DISCUS, weight, direct observation of behaviour.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Al-Kaisi-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: adults, mental handicapped inpatients with disturbed behaviour.<BR/>Interventions: sulthiame - not an antipsychotic.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-11 15:24:44 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Aman-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 15:24:44 +0000" MODIFIED_BY="Cathy Bennett">
<P>Allocation: randomised - Latin square, crossover.<BR/>Participants: "moderately to profoundly retarded residents", age range 8-35 years.<BR/>Interventions: high dose haloperidol versus low dose haloperidol versus placebo. Three week duration.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aman-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: review of atypical antipsychotic medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barnard-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: systematic review of atypical antipsychotics in autism.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Buitelaar-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: 33 boys with slightly subaverage/borderline/mild mental retardation.<BR/>Interventions: risperidone vs placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Burk-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: double blind.<BR/>Participants: mentally retarded children.<BR/>Intervention: haloperidol vs placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-11 15:25:18 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Davis-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 15:25:18 +0000" MODIFIED_BY="Cathy Bennett">
<P>Allocation: random order.<BR/>Participants: profoundly retarded institutionalised boys.<BR/>Interventions: methylphenidate vs thioridazine vs placebo vs no drug.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hacke-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, not otherwise specified.<BR/>Participants: 69 women, longstanding aggression and self injurious behaviour on neuroleptic medication. Not reported as learning disabled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hammock-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heistad-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Izmeth-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: inpatients with "mental handicap" with behavioural and / or psychiatric disorders.<BR/>Interventions: withdrawal of zuclopenthixol decanoate vs continuation of same. This is a drug withdrawal study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-11 15:25:20 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Karsten-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 15:25:20 +0000" MODIFIED_BY="Cathy Bennett">
<P>Allocation: randomised.<BR/>Participants: "oligophrenic" in-patients with mental illness, agitation and violence, children and adults. All mentally ill.<BR/>Interventions: cis(Z)-clopenthixol versus haloperidol versus placebo.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lindholm-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, double-blind, crossover.<BR/>Participants: "institutionalized mentally retarded" children and some adults.<BR/>Interventions: dixyrazine (Esucos) versus placebo. Duration of trial appears to be 10 days for each intervention.<BR/>Individual data reported for adults meeting entry criteria for this review (N=2), also Table I presents data for before first crossover, however typographical error results in data from one person being lost.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mace-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: 30 people with mental retardation and self-injurious behaviour. Only two were adults.<BR/>Interventions: haloperidol vs placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McConahey-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover.<BR/>Participants: institutionalised women with mental retardation.<BR/>Interventions: chlorpromazine vs placebo and behaviour modification.<BR/>Outcomes: no usable data reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-11 15:25:38 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Millichamp-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 15:25:38 +0000" MODIFIED_BY="Cathy Bennett">
<P>Allocation: not randomised, "double-blind" five phase study.<BR/>Participants: "profoundly mentally retarded institutionalized" adults.<BR/>Interventions: methotrimemrozine or chlorpromazine continuation or withdrawal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nielsen-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Remington-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: 36 individuals recruited from the Autism and Pervasive Developmental Disorder Clinic with autism. 24 were children. <BR/>Interventions: clomipramine vs haloperidol vs placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schroeder-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: 3 individual crossover trials. Not randomised to treatment or control.<BR/>Participants: 3 people, 2 female, 1male with profound mental retardation and self-injurious behaviour.<BR/>Interventions: clozapine versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sime-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, no further details.<BR/>Blindness: not described.<BR/>Design: crossover.<BR/>Participants: "severely handicapped" in-patients with serious behaviour disorders.<BR/>Interventions: beclamide (Nydrane) vs placebo.<BR/>Excluded as quality criteria not met.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-11 15:25:53 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Singh-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 15:25:53 +0000" MODIFIED_BY="Cathy Bennett">
<P>Allocation: randomised, crossover.<BR/>Blindness: double-blind.<BR/>Participants: "severely retarded" people with chronic behavioural problems, mixture of children and adults (mean age 15.79 years SD 4.06).<BR/>Interventions: standard dose thioridazine versus individual dose versus placebo.<BR/>Unable to extract any data from this study pertaining to adults.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Singh-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: inpatients with "mental handicap" inpatients with behaviour disorders with or without psychiatric disorder.<BR/>Interventions: continuation of zuclpenthixol versus its withdrawal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vaisanen-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover.<BR/>Participants: restless "mentally retarded" inpatients.<BR/>Interventions: sulpiride or chlorpromazine versus placebo, five day washout.<BR/>Outcomes: not usable as rating scale not described. <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vaisanen-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover.<BR/>Participants: restless "mentally subnormal" inpatients.<BR/>Interventions: haloperidol versus thioridazine, placebo washout, not placebo controlled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-11 15:25:59 +0000" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Vanden-Borre-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 15:25:59 +0000" MODIFIED_BY="Cathy Bennett">
<P>Allocation: randomised, crossover.<BR/>Participants: those with "mental retardation" with persistent behavioural disturbances.<BR/>Interventions: risperidone versus placebo.<BR/>Duration: three weeks.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wardell-1958">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: 82 severely retarded, adult, ambulatory females with behavioural disturbance.<BR/>Interventions: chlorpromazine vs reserpine vs placebo.<BR/>Outcome: behavioural rating - unable to use.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weir-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: "mentally subnormal" in-patients, mostly children and a few adults.<BR/>Interventions: pericyazine versus chlorpromazine versus placebo.<BR/>Data could not be extracted for adults.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-White-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, crossover.<BR/>Participants: "moderate to profound mental retardation with maladaptive behaviours", majority children (mean age 15.7 year SD 3.42).<BR/>Interventions: pimozide versus placebo.<BR/>Could not extract data for adults.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Williams-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: case series.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wright-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: 18 adults with severe learning disabilities.<BR/>Interventions: thioridazine vs haloperidol vs placebo.<BR/>Outcomes: unable to use data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zarcone-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: 20 individuals with developmental disabilities.<BR/>Interventions: high dose vs low dose risperidone. Not placebo controlled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zimmermann-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review of literature.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ABC - Aberrant Behavior Checklist<BR/>ABS - Adaptive Behavior Scale<BR/>DISCUS - Dyskinesia Identification System: Condensed User Scale<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Lipman-1981">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Albert-1977">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-De-Cuyper-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Elie-1980">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lynch-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McDougle-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McKenzie-1966">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zwanikken-1973">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-de-Koning-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-van-Hemert-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-11 15:29:37 +0000" MODIFIED_BY="Cathy Bennett">
<COMPARISON ID="CMP-001" MODIFIED="2008-11-11 15:29:37 +0000" MODIFIED_BY="Cathy Bennett" NO="1">
<NAME>ANY ANTIPSYCHOTIC DRUG vs PLACEBO</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.37809873630193397" CI_START="0.010020145470324439" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.06155163961984455" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.42239477415297355" LOG_CI_START="-1.9991259734287943" LOG_EFFECT_SIZE="-1.2107603737908839" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0026117539456793023" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="13" WEIGHT="100.0" Z="3.010084062049773">
<NAME>Global effect. No important clinical response - 12 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.37809873630193397" CI_START="0.010020145470324439" EFFECT_SIZE="0.06155163961984455" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.42239477415297355" LOG_CI_START="-1.9991259734287943" LOG_EFFECT_SIZE="-1.2107603737908839" ORDER="2891" O_E="-3.25" SE="0.9261797113999302" STUDY_ID="STD-McDougle-1998" TOTAL_1="11" TOTAL_2="13" VAR="1.1657608695652173" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4167244499238696" CI_START="0.3440255317348055" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6981327826472261" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.15128538905157254" LOG_CI_START="-0.46340932521895706" LOG_EFFECT_SIZE="-0.15606196808369224" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.3196330868433721" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="119" TOTAL_2="41" WEIGHT="100.0" Z="0.9952121913508406">
<NAME>Behaviour - not improved to an important extent</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.4167244499238696" CI_START="0.3440255317348055" EFFECT_SIZE="0.6981327826472261" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="23" LOG_CI_END="0.15128538905157254" LOG_CI_START="-0.46340932521895706" LOG_EFFECT_SIZE="-0.15606196808369224" ORDER="2892" O_E="-2.7562500000000014" SE="0.3610747179504182" STUDY_ID="STD-de-Koning-1994" TOTAL_1="119" TOTAL_2="41" VAR="7.670184994103773" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.708200203264372" CI_END="1.0510322269120933" CI_START="0.4773411828528199" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7083085248750378" ESTIMABLE="YES" EVENTS_1="318" EVENTS_2="121" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.02161603263672501" LOG_CI_START="-0.32117109504048796" LOG_EFFECT_SIZE="-0.14977753120188148" METHOD="PETO" MODIFIED="2008-11-11 15:29:37 +0000" MODIFIED_BY="Cathy Bennett" NO="3" P_CHI2="0.6351123355381747" P_Q="0.6351123355381747" P_Z="0.08675398883314633" Q="1.708200203264372" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="476" TOTAL_2="164" WEIGHT="400.0" Z="1.7127747406281995">
<NAME>Behaviour - other less direct measuers</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0968497347762773" CI_START="0.26278852944881487" DF="0.0" EFFECT_SIZE="0.5368794360265445" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="28" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.04014713456882993" LOG_CI_START="-0.5803935953748302" LOG_EFFECT_SIZE="-0.2701232304030001" MODIFIED="2008-11-11 15:29:37 +0000" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="1.0" P_Z="0.08794175509512987" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="41" WEIGHT="100.0" Z="1.7063563354674984">
<NAME>increased need for isolation, as required medication or restraint</NAME>
<DICH_DATA CI_END="1.0968497347762773" CI_START="0.2627885294488149" EFFECT_SIZE="0.5368794360265445" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="28" LOG_CI_END="0.04014713456882993" LOG_CI_START="-0.58039359537483" LOG_EFFECT_SIZE="-0.2701232304030001" ORDER="2893" O_E="-4.681250000000006" SE="0.3645086964950593" STUDY_ID="STD-de-Koning-1994" TOTAL_1="119" TOTAL_2="41" VAR="7.526346550707547" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.751874429414928" CI_START="0.41742329958164476" DF="0.0" EFFECT_SIZE="0.8551451366751088" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="25" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.24350297365477813" LOG_CI_START="-0.3794233133028414" LOG_EFFECT_SIZE="-0.0679601698240316" MODIFIED="2008-11-11 15:29:37 +0000" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="1.0" P_Z="0.6689006472423664" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="41" WEIGHT="100.0" Z="0.4276572943770791">
<NAME>increased need for attention</NAME>
<DICH_DATA CI_END="1.7518744294149278" CI_START="0.4174232995816448" EFFECT_SIZE="0.8551451366751088" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="25" LOG_CI_END="0.24350297365477808" LOG_CI_START="-0.3794233133028413" LOG_EFFECT_SIZE="-0.0679601698240316" ORDER="2894" O_E="-1.1687500000000028" SE="0.36590998449375667" STUDY_ID="STD-de-Koning-1994" TOTAL_1="119" TOTAL_2="41" VAR="7.468811173349057" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.086499814308577" CI_START="0.3954174208799813" DF="0.0" EFFECT_SIZE="1.1047424116600386" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="35" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.4894662551749045" LOG_CI_START="-0.40294420091668004" LOG_EFFECT_SIZE="0.04326102712911217" MODIFIED="2008-11-11 15:29:37 +0000" MODIFIED_BY="Cathy Bennett" NO="3" P_CHI2="1.0" P_Z="0.8492897043182429" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="41" WEIGHT="100.0" Z="0.19002479078655812">
<NAME>less privileges obtained</NAME>
<DICH_DATA CI_END="3.086499814308577" CI_START="0.3954174208799813" EFFECT_SIZE="1.1047424116600386" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="35" LOG_CI_END="0.4894662551749045" LOG_CI_START="-0.40294420091668004" LOG_EFFECT_SIZE="0.04326102712911217" ORDER="2895" O_E="0.36249999999999716" SE="0.524206319411199" STUDY_ID="STD-de-Koning-1994" TOTAL_1="119" TOTAL_2="41" VAR="3.6391126179245283" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3465480678985207" CI_START="0.2728816048486635" DF="0.0" EFFECT_SIZE="0.6061750553874807" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="33" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.1292218610898834" LOG_CI_START="-0.5640257394564591" LOG_EFFECT_SIZE="-0.21740193918328785" MODIFIED="2008-11-11 15:29:37 +0000" MODIFIED_BY="Cathy Bennett" NO="4" P_CHI2="1.0" P_Z="0.21896441654074772" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="41" WEIGHT="100.0" Z="1.2292865366792636">
<NAME>less social activities</NAME>
<DICH_DATA CI_END="1.3465480678985207" CI_START="0.2728816048486635" EFFECT_SIZE="0.6061750553874807" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="33" LOG_CI_END="0.1292218610898834" LOG_CI_START="-0.5640257394564591" LOG_EFFECT_SIZE="-0.21740193918328785" ORDER="2896" O_E="-3.018749999999997" SE="0.4072170721918889" STUDY_ID="STD-de-Koning-1994" TOTAL_1="119" TOTAL_2="41" VAR="6.030426739386792" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.11568750801394748" CI_START="-0.37568750801394746" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.13" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.2997029199337379" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.0370707084372501">
<NAME>Behaviour - in autistic disorder (Ritvo-Freeman Real-life Rating Scale - high score = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.11568750801394748" CI_START="-0.37568750801394746" EFFECT_SIZE="-0.13" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="0.45" ORDER="2897" SD_1="0.27" SD_2="0.41" SE="0.12535307278699975" STUDY_ID="STD-McDougle-1998" TOTAL_1="14" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.05" MODIFIED="2008-11-11 15:29:00 +0000" MODIFIED_BY="Cathy Bennett" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Aggression - to others (Overt Aggression Scale - high score = poor)</NAME>
<TR>
<TH/>
</TR>
<OTHER_DATA MODIFIED="2008-11-11 15:29:00 +0000" MODIFIED_BY="Cathy Bennett" ORDER="8" STUDY_ID="STD-de-Koning-1994">
<TR>
<TD>
<P>1. Eltoprazine: mean score 11.6, SD 8.9, N=117.<BR/>2. Placebo: mean score 11.1, SD 9.6, N=41.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.06" MODIFIED="2008-11-11 15:28:50 +0000" MODIFIED_BY="Cathy Bennett" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Aggression - to self (Social Dysfunction and Aggression Scale - self mutilation data - high score = poor)</NAME>
<TR>
<TH/>
</TR>
<OTHER_DATA MODIFIED="2008-11-11 15:28:50 +0000" MODIFIED_BY="Cathy Bennett" ORDER="9" STUDY_ID="STD-de-Koning-1994">
<TR>
<TD>
<P>1. Eltoprazine: mean score 1.7, SD 1.4, N=103.<BR/>2. Placebo: mean score 1.7, SD 1.5, N=37.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="13.217573702883552" CI_END="2.864439809326341" CI_START="1.0726825299686489" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.752893191729346" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="23" I2="24.343149319315728" I2_Q="28.41423431331062" ID="CMP-001.07" LOG_CI_END="0.457039700821248" LOG_CI_START="0.03047120762902953" LOG_EFFECT_SIZE="0.24375545422513878" METHOD="PETO" NO="7" P_CHI2="0.21176033722194954" P_Q="0.20147831184110565" P_Z="0.025092384279133708" Q="9.778480306597567" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="769" TOTAL_2="311" WEIGHT="800.0" Z="2.2399774898573734">
<NAME>Adverse effects - various by 8 to 12 weeks</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.8547590932788549" CI_END="8.057839636871366" CI_START="0.6583948091545833" DF="1.0" EFFECT_SIZE="2.303310615161611" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.9062186200249477" LOG_CI_START="-0.1815136018000509" LOG_EFFECT_SIZE="0.3623525091124484" NO="1" P_CHI2="0.35520957362541006" P_Z="0.19160963510522896" STUDIES="2" TAU2="0.0" TOTAL_1="130" TOTAL_2="54" WEIGHT="100.0" Z="1.305832176924114">
<NAME>agitation</NAME>
<DICH_DATA CI_END="22.807900819407564" CI_START="0.717073146204541" EFFECT_SIZE="4.0441232917523315" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.3580853157676585" LOG_CI_START="-0.1444365411624265" LOG_EFFECT_SIZE="0.606824387302616" ORDER="2900" O_E="1.7937500000000002" SE="0.8825887763638758" STUDY_ID="STD-de-Koning-1994" TOTAL_1="119" TOTAL_2="41" VAR="1.2837581073113207" WEIGHT="52.40857978362277"/>
<DICH_DATA CI_END="7.612039145372998" CI_START="0.2017296865587313" EFFECT_SIZE="1.2391829045257556" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.88150101300644" LOG_CI_START="-0.6952301862693809" LOG_EFFECT_SIZE="0.09313541336852957" ORDER="2901" O_E="0.25" SE="0.9261797113999302" STUDY_ID="STD-McDougle-1998" TOTAL_1="11" TOTAL_2="13" VAR="1.1657608695652173" WEIGHT="47.59142021637722"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06457450123678726" CI_END="3.7400354351417247" CI_START="0.257698919579742" DF="1.0" EFFECT_SIZE="0.9817347354687888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.5728757169634783" LOG_CI_START="-0.5888874022544496" LOG_EFFECT_SIZE="-0.008005842645485648" NO="2" P_CHI2="0.7994066155825358" P_Z="0.9784496266347487" STUDIES="2" TAU2="0.0" TOTAL_1="130" TOTAL_2="54" WEIGHT="100.0" Z="0.027012672362348125">
<NAME>diarrhoea</NAME>
<DICH_DATA CI_END="4.802713673324293" CI_START="0.15099579006936747" EFFECT_SIZE="0.8515806160197376" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.681486695778679" LOG_CI_START="-0.8210351611514058" LOG_EFFECT_SIZE="-0.06977423268636343" ORDER="2902" O_E="-0.20624999999999982" SE="0.8825887763638758" STUDY_ID="STD-de-Koning-1994" TOTAL_1="119" TOTAL_2="41" VAR="1.2837581073113207" WEIGHT="59.785184556426444"/>
<DICH_DATA CI_END="9.995854444133084" CI_START="0.14717153533911712" EFFECT_SIZE="1.2128912752466328" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.999819923467812" LOG_CI_START="-0.8321761794044588" LOG_EFFECT_SIZE="0.08382187203167661" ORDER="2903" O_E="0.16666666666666674" SE="1.0761235793541364" STUDY_ID="STD-McDougle-1998" TOTAL_1="11" TOTAL_2="13" VAR="0.8635265700483091" WEIGHT="40.21481544357356"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.240922360573796" CI_START="0.10228901522835446" DF="0.0" EFFECT_SIZE="0.6586347788592719" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.6274603218152811" LOG_CI_START="-0.9901710024741461" LOG_EFFECT_SIZE="-0.18135534032943249" NO="3" P_CHI2="1.0" P_Z="0.6603212703283732" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="41" WEIGHT="100.0" Z="0.4394696493724609">
<NAME>dizziness</NAME>
<DICH_DATA CI_END="4.240922360573797" CI_START="0.10228901522835446" EFFECT_SIZE="0.6586347788592719" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.6274603218152812" LOG_CI_START="-0.9901710024741461" LOG_EFFECT_SIZE="-0.18135534032943249" ORDER="2904" O_E="-0.46250000000000036" SE="0.9502046472918066" STUDY_ID="STD-de-Koning-1994" TOTAL_1="119" TOTAL_2="41" VAR="1.1075560141509435" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.466127131140393" CI_START="0.32905170756080526" DF="0.0" EFFECT_SIZE="1.85577396362009" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="1.0197860057731687" LOG_CI_START="-0.4827358511569162" LOG_EFFECT_SIZE="0.2685250773081263" NO="4" P_CHI2="1.0" P_Z="0.4835808739694549" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="41" WEIGHT="100.00000000000001" Z="0.7005548412388265">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="10.466127131140393" CI_START="0.32905170756080526" EFFECT_SIZE="1.85577396362009" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.0197860057731687" LOG_CI_START="-0.4827358511569162" LOG_EFFECT_SIZE="0.2685250773081263" ORDER="2905" O_E="0.7937500000000002" SE="0.8825887763638758" STUDY_ID="STD-de-Koning-1994" TOTAL_1="119" TOTAL_2="41" VAR="1.2837581073113207" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5197598017703435" CI_END="7.684005746639716" CI_START="1.3659661671736762" DF="1.0" EFFECT_SIZE="3.2397672568068767" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="5" I2="60.31367754587498" ID="CMP-001.07.05" LOG_CI_END="0.8855876809857239" LOG_CI_START="0.13543994268977116" LOG_EFFECT_SIZE="0.5105138118377475" NO="5" P_CHI2="0.11242801109867118" P_Z="0.007636991940470335" STUDIES="2" TAU2="0.0" TOTAL_1="130" TOTAL_2="54" WEIGHT="100.0" Z="2.667710995397243">
<NAME>somnolence</NAME>
<DICH_DATA CI_END="5.767219678658991" CI_START="0.7388495928014402" EFFECT_SIZE="2.064245118965683" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="3" LOG_CI_END="0.7609664943989904" LOG_CI_START="-0.13144396169259417" LOG_EFFECT_SIZE="0.31476126635319807" ORDER="2906" O_E="2.6374999999999993" SE="0.524206319411199" STUDY_ID="STD-de-Koning-1994" TOTAL_1="119" TOTAL_2="41" VAR="3.6391126179245283" WEIGHT="70.65848283915163"/>
<DICH_DATA CI_END="47.2435799703463" CI_START="1.947528924583589" EFFECT_SIZE="9.592092498153221" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.6743427996624303" LOG_CI_START="0.28948391650827865" LOG_EFFECT_SIZE="0.9819133580853543" ORDER="2907" O_E="3.416666666666667" SE="0.8134729631267789" STUDY_ID="STD-McDougle-1998" TOTAL_1="11" TOTAL_2="13" VAR="1.511171497584541" WEIGHT="29.341517160848365"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3305383228752268" CI_START="0.051752481015665916" DF="0.0" EFFECT_SIZE="0.26240933538122485" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-001.07.06" LOG_CI_END="0.1240273878491161" LOG_CI_START="-1.2860688252800239" LOG_EFFECT_SIZE="-0.5810207187154539" NO="6" P_CHI2="1.0" P_Z="0.10627169512736581" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="41" WEIGHT="100.0" Z="1.615180116577726">
<NAME>vomiting</NAME>
<DICH_DATA CI_END="1.3305383228752263" CI_START="0.051752481015665916" EFFECT_SIZE="0.26240933538122485" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.12402738784911596" LOG_CI_START="-1.2860688252800239" LOG_EFFECT_SIZE="-0.5810207187154539" ORDER="2908" O_E="-1.9500000000000002" SE="0.8282974956808852" STUDY_ID="STD-de-Koning-1994" TOTAL_1="119" TOTAL_2="41" VAR="1.457562893081761" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.94909955872373" CI_START="0.4756762490105893" DF="0.0" EFFECT_SIZE="2.921978841677558" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.07.07" LOG_CI_END="1.2540426664805582" LOG_CI_START="-0.3226885327952627" LOG_EFFECT_SIZE="0.46567706684264765" NO="7" P_CHI2="1.0" P_Z="0.24697644550603415" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="13" WEIGHT="100.0" Z="1.1577246392499128">
<NAME>enuresis</NAME>
<DICH_DATA CI_END="17.94909955872373" CI_START="0.4756762490105893" EFFECT_SIZE="2.921978841677558" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.2540426664805582" LOG_CI_START="-0.3226885327952627" LOG_EFFECT_SIZE="0.46567706684264765" ORDER="2909" O_E="1.25" SE="0.9261797113999302" STUDY_ID="STD-McDougle-1998" TOTAL_1="11" TOTAL_2="13" VAR="1.1657608695652173" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.94909955872373" CI_START="0.4756762490105893" DF="0.0" EFFECT_SIZE="2.921978841677558" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.07.08" LOG_CI_END="1.2540426664805582" LOG_CI_START="-0.3226885327952627" LOG_EFFECT_SIZE="0.46567706684264765" NO="8" P_CHI2="1.0" P_Z="0.24697644550603415" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="13" WEIGHT="100.0" Z="1.1577246392499128">
<NAME>weight gain</NAME>
<DICH_DATA CI_END="17.94909955872373" CI_START="0.4756762490105893" EFFECT_SIZE="2.921978841677558" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.2540426664805582" LOG_CI_START="-0.3226885327952627" LOG_EFFECT_SIZE="0.46567706684264765" ORDER="2910" O_E="1.25" SE="0.9261797113999302" STUDY_ID="STD-McDougle-1998" TOTAL_1="11" TOTAL_2="13" VAR="1.1657608695652173" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.814996258638057" CI_START="1.4349357353996903" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.9393939393939394" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="1.0340263735344142" LOG_CI_START="0.15683245132348433" LOG_EFFECT_SIZE="0.5954294124289493" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.007795450265795968" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="13" WEIGHT="100.00000000000001" Z="2.6608032138552944">
<NAME>Adverse effects - any reported</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.814996258638057" CI_START="1.4349357353996903" EFFECT_SIZE="3.9393939393939394" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0340263735344142" LOG_CI_START="0.15683245132348433" LOG_EFFECT_SIZE="0.5954294124289493" ORDER="2911" O_E="0.0" SE="0.515268052086645" STUDY_ID="STD-McDougle-1998" TOTAL_1="11" TOTAL_2="13" VAR="0.2655011655011655" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.834119025733171" CI_END="4.486502073836662" CI_START="0.38922705194753604" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3214643301110893" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.6519078728349345" LOG_CI_START="-0.4097969831435127" LOG_EFFECT_SIZE="0.1210554448457108" METHOD="PETO" NO="9" P_CHI2="0.6589817165705578" P_Q="1.0" P_Z="0.6549114086048091" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="73" WEIGHT="100.0" Z="0.44694965967996797">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="2912" O_E="0.5" SE="2.0" STUDY_ID="STD-Albert-1977" TOTAL_1="9" TOTAL_2="9" VAR="0.25" WEIGHT="9.723504513749884"/>
<DICH_DATA CI_END="5.2474229902185225" CI_START="0.2041032219918401" EFFECT_SIZE="1.0348989996408617" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.71994607371112" LOG_CI_START="-0.6901501394180198" LOG_EFFECT_SIZE="0.014897967146550027" ORDER="2913" O_E="0.04999999999999982" SE="0.8282974956808852" STUDY_ID="STD-de-Koning-1994" TOTAL_1="119" TOTAL_2="41" VAR="1.457562893081761" WEIGHT="56.69047747981937"/>
<DICH_DATA CI_END="9.995854444133084" CI_START="0.14717153533911712" EFFECT_SIZE="1.2128912752466328" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.999819923467812" LOG_CI_START="-0.8321761794044588" LOG_EFFECT_SIZE="0.08382187203167661" ORDER="2915" O_E="0.16666666666666674" SE="1.0761235793541364" STUDY_ID="STD-McDougle-1998" TOTAL_1="11" TOTAL_2="13" VAR="0.8635265700483091" WEIGHT="33.586018006430756"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2914" O_E="0.0" SE="0.0" STUDY_ID="STD-van-Hemert-1975" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-11 15:00:00 +0000" MODIFIED_BY="Cathy Bennett">
<APPENDIX ID="APP-01" MODIFIED="2008-11-11 14:56:52 +0000" MODIFIED_BY="Cathy Bennett" NO="1">
<TITLE MODIFIED="2008-11-11 14:53:39 +0000" MODIFIED_BY="Cathy Bennett">CENTRAL (The Cochrane Library) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-11 14:56:52 +0000" MODIFIED_BY="Cathy Bennett">
<P>The Cochrane Library (Up to 2003 (4))</P>
<P>mental-retardation*: ME or mentally-disabled-persons*:ME or (learning or mental* or intellect* or cognitiv*) near (difficult* or handicap* or retard* or disable* or disabilit* or deficien* or incapacit* or impair*)or ((Down or Downs or fragile) next syndrome) or phenylketonuria or oligophren* or (cognitiv* next impair*)or (subnormal* near intel*)<BR/>and<BR/>(substituted next benzamide*)or amisulpiride or antipsycho* or anti-psycho* or ANTIPSYCHOTIC AGENT or beclamide or benperidol or benzamide or butyrophenone* or chlorpromazine or clozapine<BR/>or dibenzoxazepine* or diphenylbutylpiperidine or dipiperone or dixyrazine or droperidol or eltoprazine or flupenthixol or flupentixol or fluphenazine or haloperidol or loxapine or methotrimeprazine<BR/>or milenperone or neuroleptic* or olanzapine or oxypertine or penfluridol or pericyazine or perphenazine or phenothiazine* or pimozide or pipamperone or pipothiazine or pipotiazine<BR/>or prochlorperazine or promazine or prothipendyl or quetiapine or risperidone or sertindole or sulpiride or thioridazine or tranquil* or trifluoperazine or zotiepine or zuclopenthixol</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-11-11 14:56:44 +0000" MODIFIED_BY="Cathy Bennett" NO="2">
<TITLE MODIFIED="2008-11-11 14:56:44 +0000" MODIFIED_BY="Cathy Bennett">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-11 14:56:33 +0000" MODIFIED_BY="Cathy Bennett">
<P>MEDLINE (1966 - Dec 2003)</P>
<P>(learning adj3 difficult$).tw.or (mental$ adj3 (handicap$ or retard$)).tw.or (learning adj3 (disable$ or disabilit$)).tw.or (intellect$ adj3 (disable$ or disabilit$)).tw.or (mental adj3 (deficien$ or incapacit$)).tw.<BR/>or (intellect$ adj3 impair$).tw. or (learning adj3 difficult$).tw.or down$ syndrome.tw.or (fragile adj3 syndrome).tw.or phenylketonuria.tw. or oligophren$.tw.or (cognitiv$ adj3 impair$).tw.or cognitiv$ impair$.tw.<BR/>or (subnormal$ adj3 intel$).tw.or exp Mental Retardation/ or Mentally Disabled Persons/<BR/>and<BR/>(substituted adj benzamide$).mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or amisulpiride.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]<BR/>or antipsycho$.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or anti-psycho$.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or exp Antipsychotic Agents/ or beclamide.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or benperidol.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or benzamide.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or butyrophenone$.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or chlorpromazine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or clozapine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or dibenzoxazepine$.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or diphenylbutylpiperidine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]<BR/>or dipiperone.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or dixyrazine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or droperidol.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or eltoprazine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or flupenthixol.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or flupentixol.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or fluphenazine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or haloperidol.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or loxapine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or methotrimeprazine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or milenperone.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or neuroleptic$.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or olanzapine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or oxypertine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or penfluridol.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or pericyazine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or perphenazine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or phenothiazine$.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or pimozide.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or pipamperone.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or pipothiazine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or pipotiazine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]<BR/>prochlorperazine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or promazine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or prothipendyl.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or quetiapine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or risperidone.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or sertindole.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or sulpiride.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or thioridazine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or thioxanthene$.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or tranquil$.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]or trifluoperazine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or zotiepine.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading] or zuclopenthixol.mp. [mp=title, abstract, cas registry/ec number word, mesh subject heading]<BR/>and<BR/>randomized controlled trial.pt.or controlled clinical trial.pt.or randomized controlled trials.sh.or random allocation.sh.or double blind method.sh.or single-blind method.sh.or clinical trial.pt.or exp clinical trials/ or (clin$ adj25 trial$).ti,ab.or ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.or Placebos.sh.or placebo$.ti,ab.or random$.ti,ab.or research design.sh.<BR/>or comparative study.sh. or exp evaluation studies/ or follow up studies.sh. or prospective studies.sh.or (control$ or prospectiv$ or volunteer$).ti,ab.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-11-11 14:57:38 +0000" MODIFIED_BY="Cathy Bennett" NO="3">
<TITLE MODIFIED="2008-11-11 14:57:34 +0000" MODIFIED_BY="Cathy Bennett">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-11 14:57:38 +0000" MODIFIED_BY="Cathy Bennett">
<P>EMBASE (1980 - December 2003) was searched using Ovid online and the following terms:</P>
<P>exp Mental Deficiency/ or mental patient/ or (learning adj3 difficult$).tw.or (mental$ adj3 (handicap$ or retard$)).tw.or (learning adj3 (disable$ or disabilit$)).tw.or (intellect$ adj3 (disable$ or disabilit$)).tw.<BR/>or (mental adj3 (deficien$ or incapacit$)).tw.or (intellect$ adj3 impair$).tw.or (learning adj3 difficult$).tw.or down$ syndrome.tw.or (fragile adj3 syndrome).tw.or phenylketonuria.tw.or oligophren$.tw. or (cognitiv$ adj3 impair$).tw.or cognitiv$ impair$.tw.or (subnormal$ adj3 intel$).tw.<BR/>and<BR/>exp Neuroleptic Agent/ or antipsycho$.tw.or tranquili$.tw.or neuroleptic$.tw.or phenothiazine$.tw.or chlorpromazine.tw.or fluphenazine.tw.or methotrimeprazine.tw.or pericyazine.tw.or perphenazine.tw.<BR/>or pipothiazine.tw.or prochlorperazine.tw.or promazine.tw.or thioridazine.tw.or trifluoperazine.tw.or butyrophenone$.tw.or benperidol.tw.or droperidol.tw.or haloperidol.tw.or diphenybutylpiperidine.tw.<BR/>or pimozide.tw.or thioxanthene$.tw.or flupenthixol.tw.or zuclopenthixol.tw. or substituted benzamide$.tw.or sulpiride.tw. or tricyclic dibenzoxazepine$.tw.or loxapine.tw.or oxypertine.tw.or clozapine.tw.<BR/>or olanzapine.tw.or sertindole.tw.or risperidone.tw.or eltoprazine.tw.or pipamperone.tw.or dipiperone.tw.or milenperone.tw.or dixyrazine.tw.or prothipendyl.tw.or beclamide.tw.or penfluridol.tw.or amisulpiride$.tw. or flupentixol.tw. or pipotiazine.tw. or quetiapine.tw. or zotiepine.tw.<BR/>and<BR/>clin$.tw.or trial$.tw.or (clin$ adj3 trial$).tw.or singl$.tw. or doubl$.tw.or trebl$.tw.or tripl$.tw.or blind$.tw.or mask$.tw.or ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw. or randomi$.tw.<BR/>or random$.tw.or allocat$.tw.or assign$.tw.or (random$ adj3 (allocat$ or assign$)).tw.or crossover.tw.or exp Randomized Controlled Trial/ or exp Double Blind Procedure/ or exp Crossover Procedure/<BR/>or exp Single Blind Procedure/ or exp RANDOMIZATION/</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-11-11 14:59:15 +0000" MODIFIED_BY="Cathy Bennett" NO="4">
<TITLE MODIFIED="2008-11-11 14:59:10 +0000" MODIFIED_BY="Cathy Bennett">PsycINFO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-11 14:59:15 +0000" MODIFIED_BY="Cathy Bennett">
<P>PsycINFO (1887 - December 2003)</P>
<P>(explode "Mental-Retardation" in DE) or (explode "Learning-Disorders" in DE) or (oligophren*) or ((mental* or learning or intell* or cognive*) near2 (handicap* or retard* or disab* or difficult* or impair* or subnormal*))or oligophren* or (mental* or learning or intell* or cognive*) near2 (handicap* or retard* or disab* or difficult* or impair* or subnormal*)or explode "Mental-Retardation" in DE or<BR/>explode "Learning-Disorders" in DE<BR/>and<BR/>( antipsycho* or tranquili* or neuroleptic* or phenothiazine* )or( chlorpromazine or fluphenazine or methotrimeprazine )or ( pericyazine or perphenazine or pipothiazine ) or (( prochlorperazine or promazine or thioridazine )or( trifluoperazine or butyrophenone* or benperidol )or( droperidol or haloperidol or diphenylbutylpiperidine* )) or ( pimozide or thioxanthene* or flupenthixol or zuclopenthixol ) or (substituted benzamide*)(tricyclic dibenzoxazepine*) or ( sulpiride or loxapine or oxypertine or clozapine )or( olanzapine or sertindole or risperidone or eltoprazine )or ( pipamperone or dipiperone or milenperone or dixyrazine or prothipendyl or beclamide or penfluridol )) or amisulpiride.tw. or flupentixol.tw. or pipotiazine.tw. or quetiapine.tw. or zotiepine.tw. (explode "Neuroleptic-Drugs" in DE)<BR/>and<BR/>((clinical-trial*) or (clinical trial*) or (random*) or ((double-blind*) or (double blind*)) or ("Placebo-" in DE) or (placebo*) or (clinical* stud*) or ((single-blind*) or (single blind)) or ((triple-blind) or (triple blind)) or ((control* stud*) or (comparative stud*)))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2008-11-11 15:00:00 +0000" MODIFIED_BY="Cathy Bennett" NO="5">
<TITLE MODIFIED="2008-11-11 14:59:54 +0000" MODIFIED_BY="Cathy Bennett">BIOSIS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-11 15:00:00 +0000" MODIFIED_BY="Cathy Bennett">
<P>BIOSIS (Biological Abstracts) (January 1980 to December 2003)</P>
<P>((al: (mental* or learning or intell* or cognitive n3 handicap* or retard* or disab* or difficult* or impair* or subnormal*)) or al: (oligophren*)))<BR/>and<BR/>((((((al: (eltoprazine or pipamperone or dipiperone or milenperone or dixyrazine or prothipendyl or beclamide or penfluridol)) or (((al: (sulpiride)) or al: (tricyclic w0 dibenzoxazepine*)) or al: (loxapine or oxypertine or clozapine or olanzapine or sertindole or risperidone))) or (((al: (trifluoperazine or butyrophenone* or benperidol or droperidol or haloperidol or diphenylbutylpiperidine*)) or al: (pimozide or thioxanthene* or flupenthixol or zuclopenthixol)) or al: (substituted w0 benzamide*))) or (((al: (antipsycho* or tranquili* or neuroleptic* or phenothiazine*)) or al: (chlorpromazine* or fluphenazine or methotrimeprazine or pericyazine*)) or al: (perphenazine or pipothiazine or prochlorperazine or promazine or thioridazine))) or al: (amisulpiride or flupenthixol or pipotiazine or quetiapine or zotiepine)))<BR/>and<BR/>(((((al: (crossover)) or (al: (random* n3 allocat* or assign*))) or (al: (randomi*))) or (al: (singl* or doubl* or tripl* or trebl* n3 blind* or mask*))) or (al: (clin* n3 trial*))))</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>